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ABSTRACT
CHARACTERIZATION OF A MORE CLINICALLY RELEVANT HUMAN
LEUKEMIA XENOGRAFT MODEL TO EXAMINE PERTURBATION OF
MET/SAM METABOLISM AS A NOVEL THERAPEUTIC PARADIGM FOR MLLR LEUKEMIA IN VIVO

Aditya Barve
July 26th, 2019

Acute myeloid leukemia (AML), is a heterogeneous clonal disorder
characterized by an accumulation of malignant myeloid progenitors in the bone
marrow (BM), hindering normal hematopoiesis. AML exhibits dramatic
heterogeneity in terms of cytogenetics, morphology, and chemotherapeutic
sensitivity. Therefore, the investigation of novel, efficacious AML therapeutics will
require advanced preclinical in vivo model systems, capable of recapitulating
patient specific disease heterogeneity, and induction chemotherapy outcomes. A
major focus and eventual outcome of this work was the establishment and
development of a more clinically relevant mouse xenograft model of patient AML,
that efficiently harbors patient derived xenografts (PDXs), and unlike more
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prevalent SCID models can tolerate more clinically relevant doses of DNA
damaging induction chemotherapy.
We examined the functional utility of our newly established, advanced
AML PDX model to confirm our in vitro findings that perturbation of methionine
(Met) / S-adenosylmethionine (SAM) metabolism is uniquely cytotoxic to MLLrearranged (MLL-R) leukemic cells, in vivo. We demonstrate here that
perturbation of Met/SAM metabolism decreases intracellular methylation
potential, alters global histone methylation dynamics, impairs the expression and
function of the H3K79 methyltransferase DOT1L, and induces apoptosis in MLLR leukemic cells. We show a significant extension in the survival of mice
harboring aggressive patient MLL-R leukemias, when treated with a
pharmacologic inhibitor of Met/SAM metabolism and induction therapy, as
compared to induction alone. The work featured in this dissertation establishes a
novel chemotherapy tolerant AML xenograft model, demonstrates its translational
utility, and supports the continued investigation of targeted inhibition of Met/SAM
metabolism against MLL-R leukemia.
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CHAPTER 1

BACKGROUND AND INTRODUCTION

1.1 Acute Myeloid Leukemia
The highly heterogeneous clonal disorder, acute myeloid leukemia (AML),
is defined by an accumulation of malignant immature myeloid progenitors in the
bone marrow (BM) and peripheral blood (rarely the central nervous system), that
exhibit a block in normal hematopoietic differentiation. The high degree of
observed disease heterogeneity is dependent largely on which particular myeloid
progenitor acquires oncogenic mutations, and during which stage of normal
hematopoiesis the oncogenic lesions occur.1 AML is the most prevalent form of
adult leukemia and the second most common childhood leukemia, and the
incidence of de novo AML has risen by 2.2% every year for the last 15 years.
There will be an estimated 21,380 new cases of AML diagnosed this year in the
U.S., many of them children. Modern remission induction chemotherapy of AML
using an anthracycline (doxorubicin, daunorubicin, or idarubicin) combined with
cytarabine, results in approximately 60-70% initial remission rates, but
unfortunately the overall 5-year survival remains poor at only 26%, due largely to
refractory relapse.2 Clinical care of AML has stagnated since the advent of
induction therapy in the 1970s and remains the only approved standard of care
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(SOC) frontline therapy for AML, irrespective of the dramatic heterogeneity of
patient AML in terms of cytogenetics, disease morphology, associated
prognoses, and induction chemotherapeutic sensitivity. Therefore, novel patienttailored therapies and/or treatment paradigms that are more efficacious, specific
to patient cytogenetics, and better tolerated by elderly and infant patients should
be investigated in conjunction with SOC therapy.3
The extreme heterogeneity of AML in terms of cytogenetics, morphology,
and therapeutic sensitivity present a unique challenge for oncologists both in
terms of treatment, and in classification. Initially, AML was classified according to
the French-American-British (FAB) classification system, which groups various
sub-types of AML based mainly on morphology, immunological phenotype, and
basic cytochemical criteria into eight major subtypes (FAB M0 to M7).4 The FAB
classification system was initially established by light microscopy of malignant
cells, as well as some limited cytogenetic characterization of recurrent genetic
abnormalities. The numerical hierarchy of the classification system corresponds
to the relative degree of maturity (lowest being the least differentiated), as well as
the progenitor cell type from which the leukemia developed.
The FAB classification system was revolutionary in redefining our
understanding of AML as a group of related neoplasms rather than a single
disease, and clearly recognized distinct morphology and cytogenetics as key
determinants of clinical outcomes and overall prognosis. However, this system
was found to be somewhat oversimplified, and severely lacking in certain
instances. The FAB classification system works well only in instances where the
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observed genetic lesions directly induce the observed cellular morphology and
cytochemical signaling. For example, in acute promyelocytic leukemia (APL, M4
subtype), or APL with abnormal eosinophils (M4Eo) the morphological
characteristics directly predict the genetic abnormalities, making these
classifications highly accurate.5 However, as research and screening
methodologies progressed and improved, it became evident that
morphology/cytochemisty did not always correlate with or predict observed
genetic abnormalities. Furthermore, patients diagnosed with the same proposed
sub-type of AML by morphology and immunological phenotyping, often exhibit
differences in observed genetic lesions. Additionally, there are many cases
where there is absolutely no correlation between observed genetic defects and
morphology, emphasizing the point that genetic profiling of AML provides a more
accurate system of classification and prognostic prediction. While the FAB
system was revolutionary in its recognition and characterization of AML as a
group of related myeloid neoplasia, based on morphology and cytochemical
heterogeneity, it does not accurately convey the genetic diversity and associated
clinical outcomes of the disease sub-types.
In response, the World Health Organization (WHO) developed an
alternate classification system in 2001, based on the central concept that the
sub-types of AML are actually distinct diseases through correlation of genetic,
morphologic, and clinical data. This new system of classification differs
significantly from the FAB system as it defines cases of AML into unique subgroups based on biological, clinical, and importantly genetic characteristics. The
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WHO classification system was updated in 2008 to its current format which, like
the FAB system, defines seven major AML subtypes: 1.) AML with recurrent
genetic abnormalities, 2.) AML with myelodysplatic related changes, 3.) therapyrelated myeloid neoplasms, 4.) Myeloid sarcoma, 5.) Myeloid proliferations
related to Down Syndrome, 6.) Blastic plasmacytoid dendritic cell neoplasm, and
7.) AML otherwise not categorized.6 Each major subtype is divided into specific
subcategories based on commonly observed recurrent genetic abnormalities,
detailed karyotype analyses, and molecular abnormalities, providing a much
better representation of the vastly differing genetic landscape of AML even in
morphologically similar cases. It is evident that the WHO system of classification
is far superior to the FAB system in terms of scope and descriptiveness, and
therefore has been universally adopted as the chosen classification methodology
for AML.
1.2 Clinical Therapy of AML
Contemporary SOC cytotoxic chemotherapy for AML is divided into two
distinct phases, namely induction therapy and consolidation therapy. The first
phase is designed to dramatically reduce the leukemic blast burden in the
periphery as well as the bone marrow, and eventually induce remission. Intensive
induction therapy is effective in inducing complete remission (CR) in 60-70% of
patients who are able to tolerate therapy. Sadly, over 45% of patients achieving
initial CR have a less than three-year overall survival due to relapse of refractory
disease. The SOC induction therapy regimen for young adults and healthy
elderly patients is commonly referred to as “7+3”, and utilizes a continuous
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intravenous (IV) infusion of a DNA damaging anthracycline (60 or 90mg/m 2)
administered the first three days along with continuous infusion of cytarabine
(Ara-C, 100mg/m2) for all seven days of therapy. As aforementioned, the goal of
induction therapy is to induce CR, which is clinically defined as less than 5%
blasts in the spicule containing BM aspirate, as well as a platelet count greater
than or equal to 100,000 cells/ml of blood and absolute neutrophil count greater
than 1000 cells/ul.6-8
The second phase of AML therapy, consolidation therapy, aims to prevent
subsequent disease relapse by reducing the minimal residual disease (MRD)
burden, or the surviving leukemic blasts and founder cells which remain
protected from cytotoxic drug exposure deep in the BM niche microenvironment.
These cells, which survive the initial induction therapy, are the causative agents
of refractory relapse resulting in patient mortality, and currently no FDA approved
therapies exist for relapsed and/or refractory AML. Oncologists have two options
for consolidation: 1.) HSC transplantation (HSCT) usually by allogenic BM
transplant or 2.) Additional chemotherapy with intermediate dose cytarabine
(1.5g/m2) twice daily on days 1, 3, and 5 in 3-4 cycles. These strategies are used
alone or in combination at the clinician’s discretion based on the patient’s ability
to tolerate aggressive chemotherapy, the availability of compatible BM donors,
and the patient’s AML subtype. Chemotherapeutic consolidation therapy (3-4
cycles) alone has been shown to effectively improve survival and lengthen
remission in patients less than 60 years of age, leaving HSC transplant as a last
resort in the result of relapse. Comparisons of high dose (3 g/m2) and
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intermediate dose (1.5 g/m2) cytarabine show equal benefit for patients under 60
years of age and therefore the intermediate dose became the standard of care,
while the high dose regimen showed greater efficacy in patients with CBF AML
[t(8:21); or inv(16)] or AML with mutated NPM1.9,10
In certain prognostic groups, HSCT remains the most effective long-term
therapy for AML, with up to 60% of transplanted patients achieving CR. Yet,
many patients are deemed ineligible for HSCT due to lack of suitable donors, comorbidities, or a failure to achieve CR during the induction phase. Age, was
initially thought to be the key determining factor in whether or not to use HSCT,
but new evidence has conclusively shown that transplant success is actually
dependent on remission status and co-morbidities. Improvements in conditioning
regimens, supportive care, and haplo-identical/cord grafts have allowed for a
larger percent of AML patients to become eligible for HSCT. The risk of relapse
remains significantly higher in patients treated with HSCT alone, and again many
patients are ineligible for transplant due to age or underlying co-morbidities.11,12
Therefore, the investigation of new well-tolerated therapeutics, especially ones
targeting patient specific genetic lesions, will be crucial to improving clinical
therapy of AML.
1.3 Heterogeneity of AML presentation and common genetic abnormalities
Chromosomal irregularities (deletions, translocations, tandem repeats
etc.) are observed in the majority of primary AML cases (approximately 50%),
and are well recognized as causative events driving leukemic progression and
transformation.9 These chromosomal abnormalities are directly correlated with
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varied patient survival, treatment outcomes, and remission duration making
cytogenetic analysis of AML a critical factor in determining treatment modalities.
For instance, AMLs harboring t(8;21)(q22;q22), inv(16)(p13.1q22), or
t(15;17)(q22;q12) have a universally better prognosis, and prolonged survival
time as compared to other irregularities, like alterations involving chromosomes 5
and 7 (complex karyotype AML) or 11q23, which are associated with shorter
survival and diminished chemotherapeutic sensitivity.13 Often, these genetic
abnormalities can lead to the expression of characteristic aberrant fusion proteins
(AML-ETO, PML-RARA, mixed lineage leukemia [MLL] fusions, DEK-CAN, etc.),
most of which have been directly implicated in driving oncogenic transformation
and blocking normal hematopoiesis through altered epigenetic regulation of gene
expression. Interestingly, approximately 40-50% of all AML cases are actually
cytogenetically normal (CN-AML) using conventional analysis,14 demonstrating
convincingly that AML associated genetic irregularities are not the only factor at
play during the development of myeloid leukemia. Recent work is now starting to
show that the presence or absence of specific mutations and/or altered
regulation of gene expression can be used to further delineate various types of
AML (especially CN-AML), and possibly provide novel avenues of targeted
therapy.
Experts are only beginning to understand the effects of dysregulated gene
expression patterns and mutation status, on transformation and
leukemogenesis.5 This is of special importance in people diagnosed with CNAML, which appears normal according to karyotyping analysis, and lack obvious
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genetic lesions found in other AML subtypes. As such, the prognostic value of
cytogenetic analysis is limited in these patients, but with the advent of nextgeneration sequencing, the genetic portrait of CN-AML has become much
clearer. It is now understood that on average CN-AMLs have 13 mutations, five
of which are recurrent “driver” mutations (directly causing leukemogenesis) and
eight are recurrent random “passenger” mutations.15 These mutations result in
molecular abnormalities in the proteins produced, and these abnormalities are
now being identified as key mediators of AML pathogenesis, as well as valuable
prognostic markers accurately predicting clinical outcome, and as novel
druggable targets for new therapeutic approaches.16 Mutations in several
proteins namely, nucleophosmin 1 (NPM1), Fms-Like Tyrosine kinase (FLT3),
and DNA methyltransferase 3A (DNMT3A) have come to the forefront of
investigation due to their very high relative frequency in AML, and their influence
on prognosis and treatment outcomes.
NPM1 mutations are the most recurrent molecular abnormality observed
in AML patients, and can be detected in approximately 25-30% of patients.17,18
These mutations result in the expression of a mutated protein lacking a folded Cterminal domain, which alters sub-cellular localization from the nucleus to the
cytoplasm, and this transition has been shown to greatly promote myeloid
proliferation and leukemogenesis. AMLs harboring these mutations generally
present with monocytic morphology, and have generally favorable prognostic
outcomes in the absence of other mutations (e.g. FLT3 internal tandem
duplications [FLT3-ITD]).19 AMLs with NPM1 mutations have been conclusively

8

shown to have a greater sensitivity to SOC induction chemotherapeutics and the
overall survival is greatly increased in both old and young patients as compared
to other molecular abnormalities.20 However, NPM1 mutations are also
associated with several other recurrent abnormalities like DNMT3A mutations,
FLT3-ITDs, and isocitrate dehydrogenase mutations, most of which in
conjunction with NPM1 mutations actually worsen the prognosis.21 Again, this is
a clear demonstration of the inherent heterogeneity of AML, and the importance
of cytogenetic analyses to examine potential molecular abnormalities, and guide
therapeutic intervention.
FLT3 was first identified as a critical regulator of normal hematopoiesis,
playing crucial roles in mediating proliferation and cell survival during
hematopoiesis. FLT3-ITDs in the juxta-membrane coding domain or the second
tyrosine kinase domain are detected in approximately 20% of all AML cases, and
30-45% of CN-AML. These mutations constitutively activate FLT3 promoting
aberrant, unchecked proliferation of AML blasts.22-24 Patients with AML
expressing FLT3-ITDs exhibit extreme leukocytosis and characteristic nuclear
invagination, and these mutations are universally associated with reduced
survival, decreased induction therapeutic sensitivity, and an increased risk of
relapse. When FLT3-ITDs occur in combination with other commonly recurring
AML mutations they correlate with diminished survival and increased relapse
rates, even when occurring with other normally favorable alterations, like NPM1
mutations. Finally, studies have shown that AML with mutations occurring in the
non-juxta domain coding regions have a worse prognosis, again highlighting the
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heterogeneity of AML and the clinical significance of mutational status as
predictive biomarkers for patient outcome and to guide therapeutic approaches.25
Mutations of the DNMT3A gene are detectable in approximately 18-22%
of all AML cases (34% in CN-AML), the most common being missense mutations
affecting arginine codon 822.21 These mutations have now been found to actually
be pre-leukemic and arise very early in the evolution of the disease, but also
persist even in times of CR. This finding is significant in that these mutations are
perhaps the most common mutations involving proteins that regulate gene
expression in AML.26 DNMT3A is a de novo methylase that is capable of
methylation of CpG dinucleotides in the promoter regions of target genes,
thereby mediating transcriptional silencing by blocking access of transcriptional
machinery to these promoters. This form of regulation, which is independent of
the genetic sequence, is known as epigenetic regulation and only very recently
have methylation and other epigenetic mechanisms become recognized as
relevant to leukemogenesis.27 Therefore it is logical that these mutations occur
very early in leukemic development, and may even play a causative role in AML,
by silencing genes required for maintenance of normal myeloid differentiation
and hematopoiesis. Finally, the value of DNMT3A mutations as prognostic
indicators remains hotly debated with some smaller studies finding a lowered
overall survival (OS) and disease free survival (DFS) in patients expressing these
mutations, while a much larger cohort study found no correlation between
DNMT3A mutation status and clinical outcome.21,28
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While these three mutations have the highest relative frequency of
occurrence overall in AML and occur irrespective of cytogenetic irregularities, it is
important to recognize that they represent only a small fraction of the vast array
of combinations of molecular and genetic abnormalities that have been
documented in AML. Furthermore, it becomes evident that AML in reality is a
group of extremely heterogeneous related myeloid neoplasias in terms of
morphology and cytogenetics, but more importantly these differences have been
shown to result in drastically different therapeutic outcomes and overall survival.
Therefore, the successful development of novel targeted AML therapeutics and
treatment paradigms, will require advanced in vivo model systems capable of
faithfully recapitulating the extreme genetic, epigenetic, and morphologic
variation found in primary AML. Such advanced systems must also be able to
replicate SOC induction therapy, not only as more relevant control (as opposed
to vehicle only), but also as a more clinically applicable way to test experimental
therapeutics and their translational/combinatorial efficacy.

1.4 Epigenetic dysregulation and heterogeneity in AML
Recently, epigenetic dysregulation has come to the forefront as a driving
mechanism for the induction and maintenance of AML, and more than two thirds
of patients with de novo AML have detectable epigenetic alterations.29 Aberrant
epigenetic regulation interferes with the physiological balance between gene
activation/repression required for normal hematopoiesis and differentiation,
resulting in the leukemic phenotype. The influence of epigenetic changes is only
recently starting to be fully understood in the context of both normal and
11

malignant hematopoiesis. Early epigenetic changes are crucial to normal
hematopoiesis as they regulate successive gene expression profiles that give
rise to all immune and hematopoietic lineages.30,31 For examples, DNA and
histone methylation are required to silence the expression of transcription factors
like RUNX1 and GATA3, which are required for self-renewal and pluripotency,
thereby allowing differentiation.32 Additionally, epigenomic analysis of normal
hematopoietic stem cells (HSCs) has shown that promoter regions of
transcription factors crucial for myeloid differentiation (C/EBPα, EBF1, PU.1,
PAX5 etc.) show low levels of DNA methylation and are enriched for bivalently
methylated histones (having both activating [H3K4me3] and repressing
[H3K27me3] marks).33 Dysregulation of these processes in AML is well
documented and consistent aberrant DNA and histone methylation profiles are
observed in a majority of analyzed patient samples. Interestingly, the various
subtypes of AML have unique profiles of distinct aberrant methylation, findings
that both highlight the importance of epigenetic regulation in the context of AML,
and provide a new investigational avenue for targeted, patient specific therapy.
Persuasive studies from several groups have demonstrated that many well
defined AML genetic lesions, like chromosomal translocations resulting in
characteristic oncogenic fusion proteins (e.g. PML-RARα, AML1-ETO, CBFβMYH11, MLL-fusions etc.), or mutations in key transcription factors or epigenetic
regulators (e.g. DNMT3A, NPM1, TET2 etc.) can result in aberrant recruitment of
a variety of epigenetic modifiers (DNMTs, HMTs, HDACs, etc.) to target genes
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and associated promoter histones resulting in abnormal leukemic gene
expression.34,35
These non-random chromosomal translocations and the resulting gene
rearrangements and oncofusion protein expression, are exhibited by the majority
of AML cases.36 Many of these chromosomal translocations involve loci encoding
transcriptional activators of myeloid differentiation with transcriptional effector
proteins capable of interaction with co-activator or co-repressor complexes. The
resultant fusion protein retains the DNA-binding ability of the wild-type
transcriptional activator, but gains the capacity to mediate epigenetic regulation
of gene expression through interaction with co-activator or co-repressor
complexes through its fusion moiety.37 AML therefore arises through a complex
multi-stage process mediated by an accumulation of genetic and epigenetic
changes, with the most common being recurrent genetic aberrations and their
associated oncofusion protein expression.38-40 Aberrant recruitment of epigenetic
modifiers by oncofusion proteins to the promoters of embryonic genes or genes
critical to myeloid differentiation, disrupts normal hematopoietic gene expression
resulting in AML. Consequently, normal patterns of DNA methylation and histone
modifications are disrupted in leukemic blasts, in a sub-type specific manner
depending on their driving oncofusion protein.41 Overall, the most common AML
fusion proteins can be grouped based on those that gain repressor activity (PMLRARα, AML1-ETO, and CBFβ-MYH11) thereby silencing gene expression and
those that activate gene expression (Mixed lineage leukemia [MLL]-fusions)
through altered epigenetic regulation.
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Fusion proteins that gain repressive function have been shown to do so
through their interaction and recruitment of transcriptionally repressive epigenetic
modifiers. For example, both PML-RARα and AML1-ETO fusions have been
shown to suppress gene expression through the direct recruitment of DNMTs to
various promoters, or the recruitment of co-repressor complexes (Sin3A, N-CoR,
and SMRT) and HDACs resulting in gene silencing. Interestingly, the CBFβMYH11 fusion only mediates gene silencing through recruitment of Sin3A or NCoR and HDAC8. PML-RARα can also silence gene expression through altered
histone methylation mediated through recruitment of the Polycomb complex. 38 A
common feature of these fusions is their abnormal ability to recruit repressive
epigenetic machinery to the promoters of genes required for myelopoiesis
thereby silencing their expression and driving AML.
Alternatively, MLL-fusions aberrantly activate and maintain gene
expression at inappropriate times through a variety of epigenetic mechanisms
including histone acetylation, histone methylation, or through interaction with the
nucleosome remodeling complex SWI/SNF. The normal MLL (MLL1) protein is
an activator of transcription, which works antagonistically to PcG proteins to
maintain appropriate lineage and stage specific expression of the HoxA gene
cluster, events crucial for proper hematopoietic differentiation. MLL can directly
activate transcription by catalyzing H3K4 methylation through the HMT activity of
its C-terminal SET domain42,43, and has been shown to be fused in-frame with
more than 60 different gene partners through its non-catalytic transactivatory Nterminus, in several types of leukemia. MLL rearrangement (MLL-R) correlates to
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highly aggressive disease that is poorly treated by SOC induction with extremely
high rates of relapse and low overall survival. MLL gene fusion partners are
diverse and range from cytoplasmic proteins to nuclear factors, and are
associated with AML, acute lymphoid leukemia (ALL), or biphenotypic/mixed
lineage leukemias depending on the fusion moiety. However, approximately 8090% of all MLL translocations in leukemia involve only one of six genes, all
members of super elongation complex (SEC), namely AF4, AF6, AF9, AF10,
ENL, or ELL.44 The other detected fusion partners occur at an extremely low
frequency, and many of them are identified in case studies only. Recently,
published studies have suggested quite conclusively that the six most common
MLL fusion partners share a common biochemical mechanism, by which they
modulate aberrant promoter histone methylation leading to leukemogenic gene
expression.

1.6 MLL-fusion protein signaling and functional dependence on the histone
methyltransferase DOT1L
Chromosomal translocations resulting in rearrangement of the MLL1 gene
have been associated with AML, ALL, and biphenotypic leukemia, and result in
fusion of the catalytically inactive N-terminus of MLL to a variety of binding
partners most commonly members of the SEC, suggesting an underlying general
mechanism of action.45 Over the last decade elegant work published by several
groups has shown that expression of several different MLL-fusions alone is
sufficient to drive leukemic transformation irrespective of the fusion partner, and
without additional cooperating mutations through the induction of widespread
15

epigenetic dysregulation, again suggesting a common mechanism for MLL-fusion
mediated leukemogenesis.46-51 Analyses of gene expression patterns from
patient leukemic blasts expressing several different MLL-fusions, have shown
that MLL fusion proteins preferentially upregulate and maintain expression of a
specific subset of wild-type MLL gene targets, most notably MEIS1 and the
HOXA cluster, thus disrupting the normal progression of hematopoietic gene
expression. Taken together these findings demonstrated overall that MLL-fusion
proteins likely function through a common underlying mechanism influencing
gene expression through aberrant recruitment of epigenetic machinery to
lineage-specific developmental genes leading to their constitutive expression
thus driving leukemogenesis.52-55
Genome-wide histone methylation profiling of MLL-rearranged leukemias
revealed profound abnormalities in the distribution of one particular histone
modification, H3K79 methylation, further solidifying the idea that MLL-fusions
drive leukemic progression and gene expression through epigenetic
dysregulation. Early evidence further supported this conclusion as H3K79
methylation is enriched at actively transcribed promoters and gene bodies, and
this modification was found at high levels at the promoters of the most prominent
MLL-fusion targets HOXA9 and MEIS1 in primary patient samples, human
hematopoietic progenitors transformed by MLL-ENL, or human MLL-rearranged
cell lines.56,57 These findings put particular emphasis on the importance of the
histone methyltransferase Disruptor of telomeric silencing 1-like (DOT1L), the
only known H3K79 methyltransferase, in MLL-fusion mediated leukemic gene
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expression. Several MLL-fusions have been shown to interact with DOT1L, MLLAF10 being the first identified to physically interact with DOT1L. Later seminal
work by Bitoun et. Al and Muller et. Al reported that the other common binding
partners of MLL (AF4, AF5, AF9, AF10 and ENL) exist in a complex that also
contains DOT1L and the pTEFb complex (phosphorylates stalled RNA
polymerase II [Pol II] activating transcription), dubbed the ENL-associated protein
or EAP complex. Furthermore, several other groups independently identified may
similar complexes like AEP (containing AF4, AF5, ENL and pTEFb), a complex
composed of AF4, AF9, ENL, AFF4, ELL1 and pTEFb, and DotCom (containing
DOT1L, AF9, ENL, AF10, AF17, several WNT modifiers), which have collectively
been termed super elongation complex (SEC).58-60 These discoveries prompted
the now generally accepted hypothesis that when fused to the N-terminus of MLL
retaining transactivation and DNA binding ability, each member of the SEC
complex can subsequently miss-recruit the other SEC complex members
including DOT1L to wild-type MLL target loci. Next, DOT1L presumably
methylates H3K79 at MLL target promoters, inducing transcriptionally permissive
open chromatin formation. Finally, pTEFb can recruit and stimulate the activation
of RNA Pol II to allow aberrant constitutive transcription of several MLL gene
targets, most notably HOXA9 and MEIS1. (Fig. 1.1) The extremely strong
correlation between increased H3K79 methylation and MLL-fusion target loci has
been dubbed an “epigenetic lesion”, emphasizing the unique expressional
dependence of these loci on aberrant histone methylation. 61
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Figure 1.1 Mechanisms of DOT1L dependent MLL-R mediated
leukemogenesis. Monoallelic translocations of the MLL gene result in the fusion
of the catalytically inactive N-terminus in frame with a variety of partners, most
commonly SEC complex members. These aberrant MLL fusion proteins (MLLFPs) directly drive leukemogenic gene expression by mistargeting of the SAMdependent activating H3K79 methyltransferase DOT1L to normally silenced
developmental genes like the HOXA cluster and MEIS1, driving their irregular
expression. Methylation of H3K79 by DOT1L at these promoters results in
transcriptionally permissive conformational changes, and subsequently the
functional MLL from the unfused allele can deposit the required transcriptionally
activating H3K4me3. The SEC complex and RNA Pol II remain associated with
the fusion partner portion of the MLL-FP, and can thus potently drive aberrant
transcription of leukemogenic genes upon DOT1L mediated promoter
euchromatin formation.
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More recently, several groups have convincingly shown through various
loss of function studies (shRNA-knockdown, pharmacologic inhibition, or
conditional knockout) that DOT1L mediated activation of MLL gene targets like
HOXA9 or MEIS1 through H3K79 methylation, is absolutely requisite for MLLfusion protein mediated leukemic transformation, progression and maintenance
in vitro and in vivo. Elegant studies published by several groups have shown that
genetic loss of DOT1L function is cytotoxic to MLL-rearranged cells and inhibits
MLL-fusion induced transformation (as does deletion of the HOXA9 gene or
mutation of H3K79), further supporting the currently accepted dogma of MLLfusion mediated leukemogenesis.62-64 Finally, these findings were confirmed by
the in vitro and in vivo anti-proliferative/cytotoxic efficacy of several specific SAM
competitive DOT1L small-molecule inhibitors against a variety of MLL rearranged
cells, thereby confirming the results observed by genetic loss through
pharmacologic inhibition of DOT1L catalytic activity.65-68 Currently, it appears
well-established that DOT1L activity is required for the initiation, progression, and
maintenance of MLL-rearranged leukemias through aberrant H3K79 methylation,
driving the continuous abnormal expression of leukemogenic genes like HOXA9
or MEIS1. Given the now well-established and crucial role of DOT1L in MLLrearranged leukemogenesis is mediated through the dysregulation of histone
methylation dynamics, we next investigated the effects of perturbations to
Met/SAM metabolism, a key metabolic pathway that determines the overall
intracellular methylation potential, specifically in MLL-rearranged human
leukemia in vitro and in vivo.
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1.5 Methionine and S-adenosylmethionine metabolism
The methionine (Met) and S-adenosylmethionine (SAM) metabolic
pathway is essential for cellular methylation reactions, including those involved in
epigenetic gene regulation, and SAM serves as the primary methyl donor for the
majority of cellular methylation reactions, including DNA, RNA, lipids and histone
methylation (both arginine and lysine)34,35. In addition to being the principal
methyl donor for all cellular reactions, SAM also serves as the sole source of the
propylamine moiety required for polyamine biosynthesis.69,70 The biologically
usable SAM moiety is synthesized from methionine by the enzyme methionine
adenosyltransferase 2A (MATIIA), and upon enzyme mediated donation of its
methyl group SAM forms the product S-adenosylhomocysteine (SAH), which is
further metabolized by SAH hydrolase (SAHH) to form homocysteine. 71
Homocysteine, is an obligatory intermediate in the transsulfuration pathway, and
serves as the precursor for glutathione synthesis. Alternatively, homocysteine
can be recycled back into methionine by the recycling enzyme methionine
synthase (MTR), which catalyzes the final step in methionine regeneration by
simultaneously converting 5-methyltetrahydrofolate to the biologically active
cofactor tetrahydrofolate, while transferring a methyl moiety to homocysteine
starting the cycle again.72 Importantly, the intracellular ratio of SAM:SAH dictates
the overall methylation potential of the cell, with SAH accumulation resulting in
global feedback inhibition of cellular methylation reactions, including epigenetic
methylation of DNA or histones (Fig. 1.2).73
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Figure 1.2 Simplified schematic of non-hepatic methionine and Sadenosylmethionine metabolism. Dietary methionine (Met) is first converted
into the principal biologically active methyl donor S-adenosylmethionine (SAM),
by the enzymatic action of methionine adenosyltransferase IIA (MATIIA). Sadenosylhomocysteine (SAH) is formed upon methyltransferase mediated
donation of the SAM methyl moiety, and is further converted to homocysteine
which can be recycled through methionine synthase mediated salvage.
Importantly, the intracellular ratio of SAM:SAH determines the overall cellular
methylation potential, therefore we chose to perturb Met/SAM metabolism and by
extension methylation potential by either deprivation of exogenous methionine
and/or DZA mediated SAHH inhibition and subsequent SAH accumulation.
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Therefore, it is likely that Met/SAM metabolic flux and expression of the
aforementioned enzymatic mediators are required at high levels selectively by
MLL-rearranged leukemia cells, to maintain and enforce aberrant histone
methylation contributing to the leukemic phenotype. Unlike genetic abnormalities,
epigenetic modifications are frequently reversible, and therefore may provide
new opportunities for targeted pharmacological therapies for MLL-rearranged
AML. Published literature targeting this pathway specifically in MLL-rearranged
leukemia is non-existent, and a very sparse body of work exists for targeting this
pathway as a general anti-leukemic therapy, with studies limited to small in vitro
studies using established human cell lines, and single agent pharmacological
inhibition of MATIIA or SAHH. Thus, this dissertation will rigorously investigate
methionine deprivation with and without inhibition of downstream enzymatic
mediators of the biosynthetic pathway (SAHH) in vitro and in vivo, as a novel
epigenetic treatment paradigm for MLL-rearranged leukemias, which have a
unique dependence on aberrant histone methylation to activate and maintain
enforced leukemic gene expression promoting leukemic survival and
proliferation.
1.6 Advantages of in vivo pre-clinical modeling of AML
Animal models have consistently been shown to better predict the longterm success of experimental therapeutics in clinical trials, especially for novel
AML therapeutics, as in vivo systems are capable of modeling the complex,
highly dynamic interaction between heterogeneous populations of leukemic cells
and the surrounding BM microenvironment.74 Current evidence supports the
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conclusion that specific niches within the BM microenvironment actually provide
a protected sanctuary for specific subpopulations of leukemic cells capable of
self-renewal and clonogenic proliferation, dubbed leukemic stem cells (LSCs).
Seminal studies using early xenograft models were able to establish that only the
most primitive fraction (Lin-CD34+) of patient AML cells, and not the more mature
blast population, were capable of transferring disease to primary and secondary
NOD/SCID recipient mice.75,76 It becomes evident that a hierarchy similar to
normal hematopoiesis exists in AML, with a small population of self-renewing
LSCs giving rise to a large population of mature, clonally expanded blasts. LSCs
are able to evade normal induction chemotherapy, due to their low rate of
proliferation and protection conferred by the BM microenvironment, and therefore
are thought to be the cause of the high relapse rate and mortality associated with
AML. Perhaps more alarming is the mounting data that these LSCs can actively
induce changes in the BM microenvironment not only at the structural level, but
in cytokine production and genetic/epigenetic abnormalities within supporting BM
stromal cells.77,78 Co-culture experiments have shown that HSCs cultured on BM
stroma collected from AML patients have a pronounced impairment in both selfrenewal and survival capacity, while LSCs lose neither attribute on AML or
normal stroma.
Thus, LSCs induce changes to the BM microenvironment and supporting
cells, which favor LSC survival and maintenance while simultaneously
compromising the ability to support and maintain normal HSC survival and
differentiation. These interactions add another layer of complexity, additional to
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the dramatic heterogeneity of AML, which again must be accounted for in model
systems that will ultimately be useful in the development of successful
therapeutic paradigms that will translate to clinical care. Again, in vivo animal
studies remain the only reliable way to examine the highly complex interplay
between leukemic populations (LSC and blast populations) and the protected BM
niche, and by extension the pharmacological efficacy of novel therapeutics.
Finally, in vivo methodologies have been shown to have significant advantages in
predicting success rates of experimental drugs, as compared to in vitro
techniques which often show success in the lab, but due to the lack of an
accurate organ specific extracellular environment, cross talk between hormones
or different cell types, differential metabolism, and site specific delivery fail to
show efficacy in clinical trials.79 This remains especially true for AML, as effective
novel therapeutics must be able to target the largely quiescent and protected
LSC population residing in the bone marrow, or alternatively target the bone
marrow microenvironment to make it unfavorable for leukemic growth or promote
normal hematopoiesis.
1.7 Immune deficient mice strains in AML research
First developed in the 1960s, immune deficient mice overcame a major
technical obstacle required for the successful xenotransplantation and durable
engraftment of human tissues and cells. Highly immune deficient mice
revolutionized the study of both normal and malignant hematopoietic processes
and support the differentiation and continued growth of human xenografts in vivo.
Characterized in 1962, nude or athymic mice, were the first immune-deficient
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mice capable of accepting human cells and tissues, and since then there has
been continued effort to improve patient sample engraftment through increased
immune ablation.80 Shortly thereafter severe combined immune deficient (SCID)
mice were developed, which lack the ability to initiate or maintain effective
adaptive immune responses due to an absence of functional B or T
lymphocytes.81 Immune ablation in these mice is achieved by a recessive
mutation resulting in deficient activity of the enzyme protein kinase, DNA
activated catalytic polypeptide (Prkdc), which impairs V(D)J recombination
disrupting lymphocyte maturation. Prkdc is also required for effective DNA
damage repair, and thus SCID mice are highly sensitive to DNA damaging
chemotherapeutics. SCID mice were found to be far superior in terms of human
tissue engraftment, and further refinement and immune ablation to these models
came with the development of non-obese diabetic (NOD)/SCID mice. Generated
through the introduction of the Prdkcscid gene into an inbreeding NOD strain,
NOD/SCID mice show consistently superior rates of human cell engraftment
compared to SCID mice.82,83 Around the same time similar strains of mice
displaying a SCID like phenotype were developed bearing a defective
recombination activated gene (RAG, can be either Rag1/2null) and crossed with
NOD mice resulting in NOD/Rag1/2null mice. These mice show equivalent
immune ablation and engraftment efficiency of human hematopoietic tissues
compared to the more prevalent NOD/SCID mice, but retain a functional DNA
damage repair response.84,85 Further attempts were made to improve the durable
long term engraftment, multilineage hematopoietic differentiation, and
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proliferation of human hematopoietic xenografts through transgenic approaches
allowing the expression of human hematopoietic cytokines in several iterations of
NOD/SCID and NOD/RAG1/2null mice.86
The early 2000s saw the arrival of a series of immune deficient mice with
true humanization potential, capable of not only highly efficient engraftment of
malignant human hematopoietic cells, but also well-differentiated multilineage
expansion of normal human HSCs. These strains were developed by the
introduction of a mutant IL2ry gene into NOD/SCID mice through respective
backcross mating, generating perhaps the two most widely used immune
deficient mice in hematological research, NOG and NSG mice, which are both
NOD/SCID IL-2rynull but differ in the location of the SCID mutation.87,88 The IL-2ry
is crucial to and B cell growth and is activated by several other interleukin
cytokines including IL-2, IL-4, IL-7, IL-15, and IL-21. Thus, its inactivation allowed
for enhance multilineage immune suppression and overcame inherent
“leakiness” observed in NOD/SCID mice, which eventually develop both T and B
lymphocytes with age.89 Inactivation of IL-2ry was also introduced into
NOD/Rag1/2null mice, resulting in NRG [(NOD)/Rag1/2null IL-2rynull] mice whose
equivalent immune impairment is dependent on hematopoietic specific RAG
deficiency leaving DNA damage repair intact.90
Functionally NOG, NSG, and NRG mice were a revolutionary leap in
murine xenograft model of human leukemia and show deficiencies in multiple
immune lineages well beyond lymphocytic impairment. Defects in T, B, and
natural killer (NK) cell lineages are observed in these mice, as well as markedly
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reduced macrophage and dendritic cell function.87 Dramatically enhanced
engraftment rates of human HSCs, cell lines, and primary patient leukemia have
been well documented in these strains, as well as well-defined multilineage
expansion and maturation of several distinct human hematopoietic lineages upon
normal human HSC xenotransplant when compared to parental strains. A
particularly important finding was that these mice support the differentiation and
proliferation of mature CD4 and CD8 single positive human T lymphocytes, which
do not develop in NOD/SCID mice. These strains, particularly NSG mice, have
become the predominant workhorses of hematological research focused on
studying both human leukemogenesis and hematopoiesis, in an in vivo system
that recapitulates many aspects of physiological conditions experience by normal
and leukemic hematopoietic cells in the human body. Such advanced in vivo
xenograft model systems are critical to effective preclinical investigation of novel
experimental therapeutics that go on to have a high rate of success in clinical
trials.
It is now well recognized that many mouse cytokines do not show cross
reactivity with receptors expressed on human cells, another significant hurdle in
the successful engraftment of many patient samples. Furthermore, this is a major
shortcoming as cytokine mediated signaling is known to be required for normal
and malignant hematopoiesis, and plays a role in leukemic progression and
therapeutic outcomes. Additionally, cytokine signaling is required for reliable
homing, engraftment, and proliferation of both patient leukemia samples and
normal human HSCs, which are notoriously difficult to engraft.91 In an effort to
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overcome this problem several independent groups have developed various
iterations of NOG and NSG mice expressing transgenes for a variety of human
hematopoietic cytokines (e.g. hIL-2, hIL-3, hIL-6, hGM-CSF, etc.).92,93 These
developments further improved hematological xenograft models by allowing for
efficient engraftment, differentiation and proliferation of human hematopoietic
cells in a BM specific in vivo microenvironment along with limited human cytokine
signaling.
Despite these great advances, the two most commonly utilized strains
NOG and NSG mice have a major flaw in the context of investigation of novel
leukemic therapeutics that is often overlooked. Mutation of the Prkdc gene, which
impairs V(D)J recombination resulting in the SCID phenotype, also ablates its
function in effective DNA damage repair. Therefore, these mice are highly
intolerant to DNA damaging chemotherapeutics, which are the foundation for
clinical therapy of leukemia, as they are unable to repair any drug induced DNA
lesions. This poses a significant challenge especially for the investigation of
novel AML therapeutics as the SOC frontline induction therapy combines an
anthracycline with cytarabine, both DNA damaging compounds. Anthracyclines
like doxorubicin or daunorubicin intercalate DNA thereby preventing
macromolecular biosynthesis, while simultaneously stabilizing topoisomerase II
promoting DNA strand breaks. Cytarabine (cytosine arabinoside, ara-C)
interferes with DNA synthesis through rapid conversion to a toxic DNA damaging
intermediate during S-phase DNA replication.94,95 Mice harboring SCID mediated
immune deficiencies are therefore severely intolerant to treatment with these
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drugs, even at doses that are subtoxic to other mouse strains, thereby
diminishing their utility in the investigation of novel and efficacious antileukemic
drugs. Effective translational models must be able to closely mimic patient
experience, including SOC therapy, not only as a more relevant control but also
in the investigation of innovative combinatorial therapeutics.
Recently, in 2014, our collaborators at Cincinnati Children’s Hospital
developed a new mouse strain by crossing NRG mice with NSGS mice, which
are transgenic NSG mice harboring the SGM3 triple co-injected transgenes
coding for expression of human IL-3, GM-CSF, and stem cell factor (SCF). After
genotyping the offspring, subsequent selective breeding together or with NRG
mice allowed for the removal of the SCID mutation resulting in NRGS mice,
essentially SGM3 transgene expressing NRG mice.96 NRGS mice have no
mature T, B, or NK cells due to hematopoietic RAG1 inactivation (as opposed to
a SCID mutation) and also express the three aforementioned human cytokines,
which are important for both the engraftment and support of human myeloid cells.
Since NRGS mice lack a SCID mutation they have functional DNA damage
repair and should therefore be tolerant to higher, more clinically relevant doses of
induction chemotherapeutics. Indeed, published studies from our collaborators
have shown that NRG mice are tolerant of doses of induction therapeutics that
are highly toxic to NSG mice, and maintain the inherent radioresistance that is a
hallmark of NRG mice.79 NRGS mice are truly cutting edge and uniquely suited to
modeling both normal and malignant human myelopoiesis, the influence of the in
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vivo hematopoietic microenvironment, human myeloid cytokine signaling, and
aggressive SOC induction therapy and dose escalation.

OVERALL GOALS AND SPECIFIC AIMS
It is now well established that in vivo xenograft models using immune
deficient mice consistently better predict the success of experimental
therapeutics, especially those against AML, through their ability to model
complex and dynamic interactions between leukemic cells and the protected BM
niche. Animal models of human leukemia have continued to improve over time,
with increasing immune ablation and transgenic human cytokine expression
boosting xenograft establishment and engraftment. However, despite decades of
research, approved clinical therapy of AML has remained unchanged since the
advent of cytotoxic induction therapy in the 1970, and no new AML therapeutics
have been approved for frontline therapy (except in the case of APL) singly or in
combination with the SOC. Furthermore, the majority of investigators utilize
NOD/SCID IL-2Rγnull immune deficient xenograft models, whose SCID mutation
and defective DNA repair render them intolerant to DNA damaging induction
therapeutics like doxorubicin and cytarabine. It is therefore crucial to develop and
establish a highly advanced, robust xenograft model of patient AML, is capable of
highly efficient engraftment of patient cells, modeling the influence of human
cytokines, and most importantly modeling therapeutic outcomes using a clinically
similar induction therapy regimen.
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Thus, the overall goals of this dissertation are to establish such a more
clinically relevant advanced xenograft model of both cell line derived (CDX) and
patient derived xenograft (PDX) human AML, and optimize a clinically similar,
well-tolerated, and efficacious SOC induction therapy regimen to recapitulate
clinical therapy. Furthermore, we examined the comparative utility of each strain
in the investigation of CDXs, PDXs, response to SOC induction
chemotherapeutics, and humanization potential. The final goal of this dissertation
is to utilize such an advanced preclinical model to investigate therapeutic efficacy
of targeted inhibition of Met/SAM metabolism against MLL-rearranged AML in
vivo. Preliminary in vitro data from our group has shown that perturbation of
Met/SAM metabolism is cytotoxic to MLL-translocated leukemic cells and alters
global histone methylation dynamics and gene expression, specifically
decreasing the expression and function of the histone methyltransferase DOT1L.
These findings must be confirmed in vivo to merit further investigation into the
therapeutic potential of targeting Met/SAM metabolism. The outcomes of this
study would aid in future preclinical investigation of successful AML experimental
therapeutics in vivo, while simultaneously modeling therapeutic outcomes in
combination with SOC therapy greatly enhancing the likelihood of success in
clinical trials.
Aim 1: Examine comparative engraftment efficiency of both malignant and
normal hematopoietic cells, including humanization potential plus disease
presentation of cell-line derived xenografts (CDXs) and primary and
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secondary patient derived xenografts (PDXs) in unconditioned NRG and
NRGS mice.
Profound differences were observed in both engraftment rates and
disease presentation in CDXs and PDXs in NRG and NRGS mice. As expected,
unconditioned NRG mice were incapable of harboring different AML PDXs, and
were determined to be ideal for CDX studies, showing predictable disease
latency and diffuse clinically similar presentation in the blood and hematopoietic
organs. Unconditioned NRGS mice showed high rates of PDX engraftment from
secondary transplants and primary AML, but developed clinically dissimilar
disease and solid tumor formation in CDXs, likely due to constitutive transgenic
human cytokine expression. Thus, we have established and optimized the
functional usefulness of both NRG and NRGS mice in human AML CDXs and
PDXs. Our findings conclude that both NRG and NRGS mice are powerful tools
for the investigation of malignant hematopoiesis, each with their own strengths
and limitations, as determined contextually by the experimental design.
Immune deficient mice, while indispensable to hematological research,
have the inherent flaw of lacking functional immunity. Moreover, patient PDX
models, which recapitulate patient specific disease lack the component of
functional human immunity still present in patients, thereby limiting investigation
of therapeutic efficacy, especially for novel immune therapies. Thus, we wanted
to examine the differential humanization potential of unconditioned NRG and
NRGS mice xenografted with normal enriched human umbilical cord blood (UBC)
derived CD34+ HSCs. Our findings demonstrate that only unconditioned NRGS
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mice, but not unconditioned NRG mice, are capable of durable long-term
engraftment and multilineage expansion of human HSCs. Interestingly, our data
showed that contrary to others findings, expression of human cytokines are not
detrimental to human HSC engraftment and proliferation. Our findings suggest
that the differences observed in other studies were likely attributable to the
intense ablative pre-conditioning of the mice prior to xenograft, which we
avoided. Thus, our data indicates that unconditioned NRGS mice support normal
human hematopoiesis, and may indicate that ablative pre-conditioning of mice
prior to humanization may be unnecessary and counterproductive.
Aim 2: Develop and optimize a clinically similar, effective dosing regimen
of induction therapeutics that is well tolerated in NRG and NRGS mice.
The only approved frontline therapy for AML remains revolves around
using a combination of an anthracycline and cytarabine, and has remained
unchanged since the 1970s. However, the large majority of published pre-clinical
studies involving experimental AML therapeutics compare efficacy only to a
vehicle control, and sometimes rarely a single agent (usually cytarabine). In
reality, the efficacy of new experimental therapeutics should be tested and
compared to approved SOC therapeutic outcomes, which remains problematic
due to the prevalence of SCID dependent xenograft model systems. To address
these issues, we utilized SCID-independent NRG and NRGS mice harboring
human AML CDXs and PDXs, and treated them with a modified 5+3 bolus IV
induction regimen (3 mg/kg doxorubicin for the first three days and 75 mg/kg
cytarabine all five days), using doses of chemotherapeutics that SCID mice
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cannot tolerate, but more closely recapitulate patient experience. Additionally, we
conducted dose escalation and treatment timing modulation studies using
increased doses of either drug or starting treatment 7 or 25 days post xenograft.
Our data indicate that NRG and NRGS mice can tolerate significantly higher and
more clinically relevant doses of DNA damaging induction therapeutics, and
furthermore our regimen is efficacious in prolonging the survival of mice
harboring aggressive human AML xenografts.
Aim 3: Investigate inhibition of Met/SAM metabolism as a novel therapeutic
paradigm against MLL-rearranged leukemia in vivo, in an advanced
xenograft model of patient AML, both against SOC induction and in
combination.
Preliminary in vitro data from our group has shown that perturbation of
Met/SAM metabolism through methionine deprivation or pharmacological
inhibition of downstream metabolism induces apoptosis in MLL-rearranged
leukemia, alters global histone methylation dynamics, and decreases expression
and function of the crucial histone methyltransferase DOT1L. DOT1L expression
and activity are absolutely required to maintain proliferation and leukemic
potential of MLL-rearranged leukemia, through mis-localization to normally
silenced embryonic gene promoters driving expression. Loss of DOT1L
expression or function is sufficient to stop MLL fusion protein induced leukemic
transformation and inhibits the proliferation and survival of MLL-translocated
leukemia cells. Inhibition of downstream Met/SAM metabolism significantly
prolonged the life of mice xenografted with aggressive pediatric MLL-translocated
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leukemia samples in combination with SOC induction therapy. Thus,
confirmation of our in vitro findings in vivo may reveal targeted inhibition of
Met/SAM metabolism through dietary or pharmacologic methods, as a novel
therapeutic paradigm against MLL-translocated leukemia, meritorious of further
investigation.
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CHAPTER 2

ESTABLISHING A MORE CLINICALLY RELEVANT MOUSE MODEL OF
PATIENT AML AND STANDARD OF CARE CHEMOTHERAPY, TO
INVESTIGATE THE THERAPEUTIC POTENTIAL OF ALTERATIONS TO
MET/SAM METABOLISM

INTRODUCTION
The study of normal and malignant hematopoietic processes has truly
been revolutionized by immune deficient mice, capable of supporting the growth
and differentiation of human hematopoietic cells and tissues without rejection. 9799

More importantly, in vivo xenograft models of human cancers consistently

better predict the success of experimental chemotherapeutics in clinical trials,
likely due to the complex and dynamic interplay existing between the BM
microenvironment and heterogenous populations of leukemic cells. 100 Several
seminal studies using early human leukemia xenograft models showed that only
the most primitive and undifferentiated fraction of patient leukemic cells
(Lin-,CD34+), but not the mature blast population, was capable of transmitting
disease to primary and secondary immune deficient mice. These cells were
dubbed LSCs, and exist at the apex of a hierarchy similar to HSCs during normal
hematopoiesis.76 This small population of slowly proliferating, self-renewing LSCs
reside within the BM niche microenvironment, and can eventually give rise to a
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large population of rapidly proliferating, clonally expanded blasts. Furthermore, a
large body of evidence supports the notion that specific niches within the BM
provide a chemotherapeutic protected sanctuary which the LSCs occupy, thereby
eventually driving lethal refractory relapse in the majority of patients who
experience initial remission.101,102 Logically, it becomes evident that xenograft
models of are the most reliable preclinical method capable of modeling the highly
complex interplay among patient specific heterogenous leukemic populations, the
BM microenvironment, clincal therapeutic outcomes, and by extension the true
pharmacological efficacy and utility of novel investigational
chemotherapeutics.103-105 Despite the great advances made in murine leukemic
xenograft models many samples of patient AML fail to sufficiently engraft, likely
due to the following factors: 1.) Improper homing to BM nice 2.) Residual mouse
innate immunity, 3.) Absence of human cytokines, 4.) Lack of appropriate stromal
support, or 5.) AML sample intrinsic factors.
Transgenic approaches have dramatically enhanced the engraftment
efficiency of human AML, by allowing the development of several iterations of
immune deficient mice capable of expressing several human myeloid cytokines
(IL-3, GM-CSF, and SCF), most frequently on NOD/SCID IL-2Rynull background
mice in hematologic research. (NSGS, NSS, etc.). Human myeloid cytokine
expression not only supports myelopoiesis and engraftment of a variety of patient
AML samples, but also the establishment and multilineage expansion of mature
human hematopoietic cells from CD34+ human HSCs.87,88,106,107 These
advances, while indeed highly significant, are hindered by the reliance on SCID-
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mediated immune deficiency (Prdkcscid), which also impairs DNA damage repair,
making these strains extremely intolerant to DNA damaging AML therapeutics
like anthracyclines and cytarabine.79,100 Thus, it becomes impossible to model
patient xenograft response to SOC therapy in the most commonly used strains in
hematologic research, despite such data being an absolutely necessary
component of more physiologically and clinically relevant in preclinical
investigation of new efficacious AML therapeutics. In 2003, Schultz et. Al
developed another strain of comparably immune deficient mice with an intact
DNA damage response dubbed NRG mice (NOD/Rag1/2null IL-2Rynull), whose
immune ablation is maintained through a defective RAG gene.
Recently in 2014, in an effort to further improve engraftment rates of
human AML samples in DNA damaging chemotherapeutic tolerant mice, NRG
mice were crossed with human cytokine expressing NSGS (NSG-hIL3, h-GMCSF, hSCF) mice and the SCID mutation removed through selective
backcrossing with NRG mice. The resultant strain called NRGS (NRG-SGM3)
mice express human myeloid cytokines, display a comparable degree of immune
ablation to SCID mice, and can likely tolerate higher doses of SOC therapeutics
in a clinically similar dosing regimen.79 NRGS mice show consistent highly
efficient engraftment of human hematopoietic cells, and can model the influence
of the BM microenvironment, human cytokine signaling, and therapeutic
outcomes. Given the recent development of these strains, and their relative lack
of use in AML research, we next conducted an in-depth analysis of the
comparative utility of unconditioned NRG and NRGS mice for the study of CDXs,
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patient derived xenografts (PDXs), response to SOC chemotherapeutic treatment
in clinically similar dosing regimen, and finally humanization potential using
purified human HSCs.

MATERIAL AND METHODS
Cell Culture and Patient Samples. Established human AML cell lines K562,
MV411, and U937 were obtained from American Type Culture Collection (ATCC,
Rockville, MD, USA) and cultured in RPMI medium supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin at 37°C with 5% CO2. The patient
derived xenograft models (CCHMC-23, CCHMC-7, CCHMC-9, and CCHMC-35),
were established at Cincinnati Children’s Hospital Medical Center from
specimens acquired under an IRB-approved protocol following informed consent.
These primary specimens were established and expanded in NSGS mice at
CCHMC and BM aspirates obtained from leukemic mice were frozen at -80°C in
RPMI with 10% FBS and 10% DMSO until xenograft. Primary AML blasts were
isolated from de-identified diluted whole marrow aspirate acquired from JGBCC
biorepository with informed consent and under IRB guidelines (IRB#13.0188), by
Histopaque gradient and centrifugation at 500 x g for 20 minutes at room
temperature. Human CD34+ hematopoietic stem cells purified from umbilical
cord blood were obtained from AllCells, Alameda, California, USA).
In vivo studies. NRG (NOD/RAG1/2−/−IL2Rγ−/−, stock no: 007799) and NRGS
(NOD/RAG1/2−/−IL2Rγ−/−Tg[CMV-IL3,CSF2,KITLG]1Eav/J, stock no: 024099)
mice producing 2-4 ng/ml of human IL-3, GM-CSF, and SCF108 were obtained
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from Jackson laboratories, and bred and maintained under standard conditions in
the University of Louisville Rodent Research Facility (RRF) on a 12-hour light/12hour dark cycle with food and water provided ad libitum. Animal procedures were
approved by the Institutional Animal Care and Use Committee. For all cell line
derived xenograft studies and the human HSC study mice received 5 x 10^5
cells, and for all passaged patient derived xenograft studies 1.25 x 10^5 human
cells suspended in 200µl PBS per mouse by bolus intravenous injection.
Similarly, mice engrafted with the primary patient sample JGB-AML1 received 2 x
10^6 cells in 200 µl per mouse by intravenous bolus. Mouse health was
monitored for characteristic signs of leukemia like scruffiness, and hind-limb
paralysis, at which time mice were euthanized. Analysis of human cell
engraftment was conducted on a case-by-case basis when mice became
moribund and humane endpoints were reached.
5+3 Induction Chemotherapy Regimen. Using previously published data we
established a similar 5+3 induction therapy regimen using intravenous bolus
injection of doxorubicin (3 mg/kg, Days 1-3) combined with cytarabine (75 mg/kg,
Days 1-5). Mice began treatment seven (or twenty five) days after transplantation
of human leukemic cells with all mice receiving injections balanced to a final
volume of 200ul PBS. Patients receiving standard 7+3 induction therapy (60
mg/m2 doxorubicin and 100 mg/m2 cytarabine) get approximately 1.5 mg/kg
doxorubicin and 2.5 mg/kg cytarabine. Therefore, similar to previously published
work, our dose of doxorubicin was doubled and the cytarabine concentration
increased by 20-fold in an attempt to achieve necessary plasma concentrations
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of the drugs using a bolus injection as compared to continuous infusion given in
clinical care.79
Chemotherapeutics. Clinical formulations of both doxorubicin and cytarabine
were obtained from the James Graham Brown Cancer Center as self-sealing
vials containing 20 mg/10 ml or 2g/20ml respectively dissolved in saline,
manufactured by APP a division of Fresenius Kabi USA LLC (Lake Zurich, IL).

FACS Analysis. The spleen and BM cells were analyzed by FACS as previously
described.109 Briefly cells were isolated from tissues, red blood cells were lysed
and blocked for 10 mins at 4°C with Fc Block (#553142 BD Biosciences, Miami,
FL, USA). The samples were then stained with the appropriate fluorophore
conjugated anti-human antibody (Alexa 700-CD45, APC-CD11b, APC-CD19, PECD3, PE-Cy.5-CD34, and PE-Cy.5-CD33) from BioLegend (San Diego, CA) for
20 mins at 4° C and then analyzed on a Becton Dickinson FACScan with FlowJo.
Statistical analysis. All statistics were performed using GraphPad Prism 6
software. Unless specified below significance was determined by one-way
ANOVA, followed by Tukey tests, using a cut off of P < 0.05. For all survival
curves the log rank (Mantel-Cox) test was used, with a cut off of P < 0.05.

RESULTS

Cell line derived xenografts (CDXs) recapitulate clinical disease
presentation in unconditioned NRG mice, but not unconditioned NRGS
mice.
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We first wanted to examine the differential engraftment efficiency of
several commonly used, well- characterized human leukemic cell lines (MV411,
K562, and U937) in unconditioned NRG and NRGS mice. All established cell
lines showed high rates of successful engraftment in both strains, leading to
leukemic disease progression and eventual euthanasia upon achievement of
humane endpoints. (Fig. 2.1A) Interestingly, clinically disparate disease
presentation was observed selectively in NRGS mice, which developed large
intraperitoneal (IP) and lymphatic solid tumors with all cell lines tested.
Conversely, NRG mice developed more clinically similar diffuse disease with the
expected signs of leukemic disease progression like splenomegaly, upon
xenograft of all established human cell lines. Necropsy of NRGS mice revealed
disparity in preferential location of solid tumor formation with MV411 cells forming
both IP and lymphatic tumors (Fig. 2.1B, bottom right), K562 cells had an
extremely high potential to form tumors within the kidney (Fig. 2.1B, bottom
left), and U937 cells formed only intra-splenic solid tumors (Fig. 2.1B, bottom
middle). All mice showed high levels of engraftment with any of these cell lines,
and showed pronounced leukemic infiltration of hematopoietic organs (Fig. 2.2A
and 2.2B), but only NRG mice selectively failed to develop IP masses or
hematopoietic solid tumors and showed a much more clinically relevant disease
progression. Therefore, these studies provide compelling evidence that NRG
mice, but not NRGS mice, are well suited for experimental studies involving
CDXs.
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Figure 2.1. Engraftment of established human AML cell lines in NRG and
NRGS mice. (A) Survival curves of unconditioned NRG and NRGS mice post IV
xenograft of 5 x 105 of each respective cell line, K562, U937, and MV411. (B)
NRG mice transplanted with human AML cell lines showed normal leukemic
progression with diffuse disease and splenomegaly (as depicted), whereas
NRGS mice developed solid splenic tumors (U937), solid IP tumors (K562,
MV411), and solid lymphatic tumors (MV411). (C) Box-and-whisker plots
showing the percentage of detectable human cells in the spleens and BM of
NRG (n = 5) and NRGS (n = 5) mice, as quantified by flow cytometry for human
CD45. AML, acute myeloid leukemia; BM, bone marrow; IP, intraperitoneal.
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Figure 2.2 H&E staining of spleen sections from NRG and NRGS mice
xenografted with established human cell lines. (A) H&E-stained sections of
representative formalin-fixed spleens from unconditioned NRG mice IV
xenografted with 5 x 105 K562, MV411, or U937 cells per mouse suspended in
200 mL of PBS. (B) Representative spleens from unconditioned NRGS mice IV
xenografted with 5 x 105 K562, MV411, or U937 cells per mouse suspended in
200 mL of PBS. PBS, phosphate-buffered saline.
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Patient derived xenografts (PDXs) in unconditioned NRG and NRGS mice.
We next examined the comparative engraftment efficiency of several
patient-derived AML samples in both NRG and NRGS mice. Patient-derived
samples were acquired as secondary transplants from NSGS mice harboring
pediatric patient leukemia taken upon relapse, and three of the four samples
displayed MLL translocations, whereas the final sample tested was
cytogenetically normal (Fig. 2.3A). Leukemic disease progression eventually
requiring euthanasia occurred in all NRGS mice irrespective of sample origin,
while all NRG mice survived until the 100-day study endpoint without overt signs
of disease (Fig. 2.3B). As expected efficient engraftment and leukemic infiltration
of the hematopoietic compartment occurred with all four patient-derived samples
in NRGS mice, whereas three of the four patient samples tested (CCHC-7,
CCHC-23, and CCHC-35) showed virtually no useful engraftment (<5%) in NRG
mice (Fig. 2.3C). Interestingly, large numbers of human cells were detected in
the hematopoietic organs of NRG mice engrafted with CCHC-9 cells, but without
symptomatic leukemic disease progression. Furthermore, no IP or lymphatic
solid tumors formed in NRGS mice harboring PDXs, thus providing convincing
evidence that NRGS mice, but not NRG mice, are uniquely suited for studies
involving patient-derived leukemia cells.
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Figure 2.3. Engraftment of patient-derived AML cells in NRG and NRGS
mice. (A) All patient samples were initially obtained from pediatric patients upon
relapse and passaged once through NSGS mice. All xenograft experiments
performed in these studies utilized the BM of NSGS mice harboring high levels of
each respective patient leukemic cells, as quantified by flow cytometry for human
CD45. (B) Survival curves of NRG and NRGS mice after IV xenograft of 1.25 x
105 human cells of each respective patient sample. Mice showing no signs of
disease were euthanized 100 days after xenograft, the end-point of the study. (C)
Box-and-whisker plots showing the percent of detectable human cells in the
spleens and BM of NRG (n = 5) and NRGS (n = 5) mice, as quantified by flow
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cytometry for human CD45. AML, acute myeloid leukemia; BM,
bone marrow.
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Humanization potential of unconditioned NRG and NRGS mice using
purified human CD34+ HSCs.
Given the recent push for the development of humanized mice bearing
functional human immunity, we next examined the differential engraftment
potential and the multilineage expansion of normal human CD34 + HSCs. CD34+
cells purified from umbilical cord blood (Fig. 2.4A) were transplanted into
unconditioned NRG and NRGS mice, but only NRGS mice showed significant,
durable engraftment of human hematopoietic cells 105 days later. Human cells
were still detected in the hematopoietic organs of NRG mice, albeit at an
extremely low percentage. Hematoxylin and eosin staining of spleen sections
from NRGS mice revealed distinct patches of human cells absent in NRG mice,
likely human HSCs undergoing extramedullary hematopoiesis (Fig. 2.4B)
Multilineage expansion of human myeloid cells, pre-B cells, and T cells was
observed selectively in NRGS mice, as characterized by surface expression of
human CD19, CD33, and CD3 respectively (Fig. 2.4C). In contrast to previously
published work indicating transgenic human cytokine expression is
counterproductive to human HSC engraftment, we show that unconditioned
NRGS mice retain high levels of human HSCs (huCD45+/huCD34+) in the spleen
(Fig. 2.5A) and BM (Fig. 2.5B) even 105 days after xenotransplantation.
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Figure 2.4. Comparative humanization potential of NRG and NRGS mice
using human umbilical cord-derived CD34+ HSCs. (A) Histogram showing the
percentage of human CD34+ cells purified from UCB before xenotransplantation.
Blue indicates unstained cells and red indicates cells stained with antihuman
CD34-PE/Cy5. (B) Immunohistochemistry analysis with H&E staining of
representative NRG and NRGS spleens. Distinct patches of human cells are
clearly visible only in NRGS spleens. (C) Box-and-whisker plots showing the
percentage of human cells in the spleens and BM of NRG (n = 3) and NRGS (n =
3) mice 105 days after transplantation of 5 x 105 human CD34+ cells and lineage
analysis by FACS staining using antihuman CD45-Alexa Fluor 700 (human pan-
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hematopoietic), CD19-APC (pan-B cell), and CD33-PE/Cy5 (pan-myeloid). UCB,
umbilical cord blood.
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Figure 2.5. Comparison of long-term engraftment of mature and stem
human hematopoietic cells in unconditioned NRG and NRGS mice. (A)
Representative flow plots and relative percentages of human stem
(huCD45+/huCD34+) and mature (huCD45+/huCD34-) hematopoietic cells in the
spleens of unconditioned NRG (n = 5) and NRGS (n = 5) mice 105 days after
transplantation of 5 x 105 human CD34+ UBC cells, indicating significantly higher
engraftment of both stem and mature human hematopoietic cells. (B)
Representative flow plots and relative percentages of mature and stem human
hematopoietic cells detected in the BM of unconditioned NRG and NRGS mice
showing highly significant enrichment of both stem and mature human
hematopoietic cells selectively in NRGS mice.
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Establishment and comparison of clinically similar induction therapy
dosing regimen in unconditioned NRG and NRGS mice.
Truly useful AML xenograft models also require the ability to model SOC
therapeutic outcomes, which in current clinical practice relies solely on the
cytotoxic combination of an anthracycline and cytarabine. Therefore, we next
examined the tolerability and efficacy of an adapted 5+3 induction regimen in
both NRG and NRGS mice xenografted with human leukemic cells. Xenograft of
the established cell lines MV411 and K562 resulted in solid tumor formation and
clinically disparate disease presentation in NRGS mice. Mice injected with U937
cells show similar survival trajectories, and engraftment efficiency in both strains,
with NRGS solid tumor formation restricted to the spleen. Further, given the
previous findings that PDX samples fail to engraft efficiently in NRG mice we
chose U937 cells to examine comparative SOC therapeutic outcomes in both
unconditioned NRG and NRGS mice. NRG and NRGS mice were able to tolerate
our adapted 5+3 bolus IV induction therapy regimen, and all treated mice showed
highly significant enhancement in survival as compared to vehicle-injected
controls (Fig 2.6A). Our findings indicate that both strains are tolerant of a more
clinically similar induction dosing regimen, and furthermore induction therapy in
efficacious in treating disease (Fig 2.6B). Comparison of PDX induction
sensitivity in NRG and NRGS mice proved a challenge as none of the four
patient samples (CCHC-7, CCHC-9, CCHC-23, and CCHC-35) gave rise to
leukemia in NRG mice at the time points examined. Although the inherent
limitations of NRG prevented comparative examination of SOC therapeutic
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outcomes with patient-derived AML xenografts, we still felt that it was important
to test the efficacy of our regimen against AML PDXs. Therefore, unconditioned
NRG and NRGS mice were engrafted with the patient sample CCHC-23 and 5+3
induction therapy was initiated 7 days post xenograft. Again, 5+3 induction
therapy significantly prolonged the life of all treated NRGS mice compared to
vehicle-injected controls (Fig 2.6C), and therapy significantly reduced the
leukemic burden. NRG mice in this study again failed to develop disease and
survived until the experimental endpoint. Similarly, our adapted 5+3 induction
therapy regimen was also efficacious in significantly prolonging the life of NRGS
mice harboring either CCHC-7 or CCHC-9 PDXs (Fig 2.6D). Take together these
findings indicate that our newly established adapted 5+3 induction therapy
regimen is efficacious against several different patient-derived AMLs of varied
etiology, at rates comparable to those observed in the aforementioned study
using the established U937 cell line. These data are crucial to establishing the
feasibility and efficacy of modeling SOC induction therapeutic outcomes in mice
bearing AML PDXs.
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Figure 2.6 Comparison of standard of care chemotherapeutic response
using 5+3 induction regimen in NRG and NRGS mice harboring cell line or
patient-derived leukemia. (A) Survival curves for unconditioned NRG (n = 5)
and NRGS (n = 5) mice engrafted with 5 x 105 U937 cells and subsequently
treated with a 5+3 induction regimen [3 mg/kg doxorubicin (days 1-3) and 75
mg/kg cytarabine (all 5 days)] or the vehicle (PBS) by IV injection 7 days after
xenograft. (B) Box-and-whisker plots showing significant differences in the
percentage of human cells detected in the spleens and BM of the NRG or NRGS
mice from the study in (A). (C) Survival curves and box-and-whisker plots
showing the percentage of human cells engraftment in unconditioned NRG (n = 5
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per group) and NRGS (n = 5 per group) mice xenografted with 1.25 x 105 CCHC23 cells, and subsequently treated with 5+3 induction or the vehicle 7 days after
xenograft. NRG mice failed to develop disease and survived until the endpoint of
the study with or without induction therapy. (D) Survival curves showing
significantly prolonged survival of unconditioned NRGS mice treated with 5+3
induction using two additional patient xenografts, CCHC-7 and CCHC-9, to
confirm therapeutic efficacy in multiple PDX samples. PBS, phosphate-buffered
saline.
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Dose escalation and modulation of adapted 5+3 induction regimen in AML
PDX bearing NRGS mice.
Having established the tolerability of NRG and NRGS mice to our adapted
5+3 induction therapy regimen, we next wanted to test the limits of our model
system by doubling the doses of both chemotherapeutics. Comparable to studies
in human patients, the dose-limiting agent in this study was determined to be the
anthracycline doxorubicin. Cohorts of mice receiving double the dose of
doxorubicin showed widespread toxicity and mortality (7 of 10 mice).
Interestingly, doubling of the cytarabine dose of cytarabine showed no overt
increase in signs of toxicity as determined by weight loss, with no change in the
survival trajectory compared to our standard 5+3 induction therapy (Fig. 2.7A,
top). Perhaps, most intriguingly the few mice that survived treatment with double
the dose of doxorubicin (6 mg/kg) showed no signs of leukemia at the endpoint of
the study (Fig. 2.7A, bottom). When taken together these data are highly
significant as they suggest that with proper optimization of drug concentration
and dosing schedule it may be possible to achieve a “remission-like” phenotype
in murine PDX models, a feature that closely recapitulates patient experience of
AML. Up to 75% of de novo AML patients experience complete remission with
only one cycle of induction therapy, with the majority of mortality being driven by
refractory relapsed disease, again highlighting the importance of our findings in
the accurate modeling of patient AML outcomes. Finally, in an effort to more
faithfully recapitulate clinical therapy of AML we examined how modulation of
treatment initiation timing affected therapeutic efficacy of our 5+3 induction
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therapy 7 days and 25 days post leukemic xenograft. Concurrent with previously
published reports we found that survival was significantly different between the
cohorts receiving induction therapy 7 days or 25 days post xenograft, with mice
receiving chemotherapy earlier surviving longer (Fig 2.7B). Finally, further
investigation and optimization of treatment schedules may allow the development
of an AML PDX model that can also accurately recapitulate clinical treatment
outcomes, including minimal residual disease, remission, and relapse.
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Figure 2.7. Escalation of 5+3 induction chemotherapy and modulation of
timing of chemotherapy initiation. (A) Survival curves of unconditioned NRGS
mice (n = 5 per group) xenografted with 1.25 x 10^5 CCHC-23 cells and
subsequently treated with 5+3 induction therapy this time with either double the
dose of both drugs (6 mg/kg doxorubicin, 150 mg/kg cytarabine), double the dose
of each drug singly without manipulation of concentration of the other or 1.5X the
standard dose of doxorubicin (4.5 mg/kg, 75 mg/kg cytarabine). Box-and-whisker
plots show the percentage of human cells detected in the spleen or BM in each
treatment escalation group. (B) Survival curves of unconditioned NRGS mice (n =
5 per group) xenografted with 1.25 x 105 CCHC-23 cells and treated with 5+3
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induction 7 days after xenotransplantation or 25 days after xenotransplantation.
Box-and-whisker plots show the percentage of human cells detected in the
spleens and BM of NRGS mice upon disease progression and euthanasia after
5+3 induction therapy initiated either 7 days or 25 days after xenograft. BM, bone
marrow.
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Primary patient sample engraftment in unconditioned NRG and NRGS mice.
The final line of investigation in this chapter examines the differential
engraftment efficiency of an un-passaged primary patient AML sample (for
detailed description, see Fig. 2.8A) obtained from a fresh BM aspirate from
The James Graham Brown Cancer Center (Fig. 2.8B). 2 x 10^6 nucleated cells
obtained from purification of the leukemic BM aspirate were injected into
unconditioned NRG or NRGS mice, and all mice were euthanized 100 days post
xenograft at which time the spleens and BM were analyzed for human CD45
expression by flow cytometry. On average, NRGS mice had consistently higher
rates of both spleen and BM engraftment as compared to NRG mice (Fig. 2.8C).
Rates of splenic engraftment were consistently low in both NRG and NRGS mice
(NRG average %huCD45= 3.07%, NRGS average %huCD45= 5.87%), with
NRGS mice harboring approximately twice as many spleen resident human cells.
H&E staining of spleen sections further confirmed these findings and revealed a
higher degree of leukemic infiltration in NRGS mice compared to NRG mice.
(Fig. 2.8D)
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Figure 2.8. Engraftment of primary patient-derived AML in NRG and NRGS
mice. (A) Initial characterization of primary patient AML sample upon acquisition
of BM aspirate and subsequent Ficoll gradient separation of mononucleated cells
by flow cytometry for human CD45, CD34, CD33, CD19, CD14, and CD11b. (B)
BM aspirate slide smear stained with Protocol Hema 3 showing both leukemic
myeloblasts (red) and monoblasts (blue) (photograph acquired at 40X on Zeiss
Observer AX10 microscope connected to a Sony Nex-5n HD camera) typical for
M4 subtype AML. (C) Box-and-whisker plot showing the percentage of human
cells detected in the spleens and BM of unconditioned NRG (n = 5) and NRGS (n
= 5) mice 100 days after xenograft of 2 x 106 mononucleated cells. (D)
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Immunohistochemistry of representative formalin-fixed, H&E-stained NRG and
NRGS spleens xenografted with 2 x 106 mononuclear cells obtained from Ficoll
gradient separation of clinical BM aspirate.
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CHAPTER 3

PERTURBATION OF MET/SAM METABOLISM INDUCES APOPTOSIS,
ALTERS HISTONE METHYLATION DYNAMICS, AND DECREASES DOT1L
EXPRESSION IN MLL-TRANSLOCATED LEUKEMIA PROLONGING
SURVIVAL IN ADVANCED PATIENT AML XENOGRAFT MODEL

INTRODUCTION

Mixed lineage leukemia 1 (MLL) gene rearrangement is a defining feature
of a unique group of particularly aggressive and chemotherapy resistant acute
leukemias. Rearrangement of the MLL gene on chromosome 11q23 results in
fusion to over 60 different partner genes, the large majority of MLL fusions
occurring with just six common partners. Furthermore, MLL-rearrangement (MLLR) is detectable in 10% of leukemia cases, which have the overall worst
prognosis among cytogenetically abnormal leukemias.110 Leukemias arising from
MLL-R result in the aberrant expression of oncogenic MLL fusion proteins (MLLFPs), and typically manifest as either acute myeloid or acute lymphoid leukemias
(AML or ALL), accounting for 10% of adult AML cases, and 70-80% of infant
leukemias.111 Modern highly aggressive multiagent cytotoxic chemotherapy and
hematopoietic stem cell transplantation (HSCT), has extended the overall
disease-free survival of pediatric leukemia patients to approximately 90%.
Unfortunately, patients diagnosed with MLL-R leukemia have a particularly poor
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prognosis with an overall survival less than 50%, and this prognosis is not
improved by allogenic HSCT.112 Great advances have been made in
understanding the unique molecular mechanisms that mediate MLL-R driven
leukemogenesis, and recently studies have suggested MLL-R leukemias are
largely driven and maintained through epigenetic dysregulation. The HMT
disruptor of telomeric silencing 1-like (DOT1L) has come to the forefront as a
critical mediator of MLL-FP mediated leukemogenesis and has been shown to be
required for the development the development, maintenance, and progression of
MLL-R leukemias. Despite our improved understanding of the unique signaling
mechanisms underlying MLL-FP mediated leukemogenesis, these leukemias are
generally still treated with cytotoxic remission induction chemotherapeutic
regimens resulting in high rates of initial remission, but the 5-year event-free
survival rates remains under 50% due to refractory relapse. Thus, novel
treatment paradigms must be investigated specifically for the therapy MLL-R
leukemias, alone and in combination with SOC cytotoxic induction
chemotherapeutics.
DOT1L, the HMT which catalyzes the sequential methylation of H3K79 at
the promoters of actively transcribed genes, has been strongly implicated as a
requisite driver of MLL-FP mediated leukemic transformation and progression.
Chromosomal translocations cause the in-frame fusion of MLL to a variety of
fusion partners, most frequently members of the SEC complex namely, AF4,
AF6, AF9, AF10, and ENL.113 These oncogenic fusions can interact directly and
indirectly with Dot1L, promoting aberrant recruitment to leukemogenic gene
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promoters like the HoxA cluster or Meis1.56 Dot1L causes local hypermethylation
of H3K79 at these gene promoters inducing their aberrant expression causing
leukemic transformation resulting in either AML or ALL.57 Several independent
studies have shown through pharmacologic and genetic methods that Dot1L
expression and function are required for both leukemic transformation and
maintenance in vitro and in vivo. Consistent with this paradigm genetic deletion
of DOT1L stops the leukemic transformation of normal HSCs transfected to
express MLL fusions and new small molecule inhibitors of Dot1L are selectively
toxic to MLL fusion driven leukemia cells in vitro and in xenograft
models.62,65,67,114,115 The investigation of regulatory mechanisms controlled by
Dot1L (cell cycle, development, transcription, DNA damage repair etc.) is
exhaustive, however the regulation of Dot1L’s own expression remains unstudied
and elusive. DOT1L mRNA is expressed ubiquitously in all organs at varying
levels, and its level is dynamically regulated during the cell cycle as are the levels
of H3K79me1,2,3.116,117 DOT1L-knockout cells transformed with MLL-fusion
proteins, DOT1L siRNA transfected human lung cancer cells, and DOT1Lknockout murine yolk sac-derived erythroid progenitors all undergo G1 cycle
arrest and eventual cell death.118-120 Given the unique dependence of MLL-FPs
on epigenetic dysregulation to drive leukemogenesis through aberrant activating
histone methylation at leukemogenic promoters, we sought to investigate
perturbation of Met/SAM metabolism as a novel therapeutic strategy for MLL-R
leukemias.
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The Met/SAM metabolic pathway is essential for cellular methylation
reactions, including those involved in epigenetic gene regulation, as SAM serves
as the primary methyl donor for most cellular methylation reactions, including
DNA, RNA, lipids and histones (both arginine and lysine).34,35 In addition to being
the principal methyl donor, SAM also serves as the sole source of the
propylamine moiety required for polyamine biosynthesis.69,70 The biologically
usable SAM moiety is synthesized from methionine by the enzyme MATIIA, and
upon enzyme mediated donation of the SAM methyl group forms the product
SAH, which is further metabolized by SAH hydrolase (SAHH) to form
homocysteine.71 Homocysteine is an obligatory intermediate in the
transsulfuration pathway, and serves as the precursor for glutathione synthesis,
and alternatively homocysteine can be recycled back into methionine by the
enzyme MTR, which catalyzes the final step in methionine regeneration by
simultaneously converting 5-methyltetrahydrofolate in the biologically active
cofactor tetrahydrofolate while transferring a methyl moiety to homocysteine
starting the cycle again.72 Importantly, the intracellular ratio of SAM:SAH dictates
the overall methylation potential of the cell, with SAH accumulation resulting in
global feedback inhibition of cellular methylation reactions, including epigenetic
methylation of DNA or histones.73
Therefore, we hypothesized that Met/SAM metabolic flux and expression
of the aforementioned enzymatic mediators are required at high levels selectively
by MLL-R leukemia cells, to maintain and enforce aberrant histone methylation
contributing to the leukemic phenotype. Unlike genetic abnormalities, epigenetic

66

modifications are frequently reversible, and therefore may provide new
opportunities for targeted pharmacological therapies for MLL-R leukemias.
Published literature targeting this pathway specifically in MLL-R leukemia is nonexistent, and a very sparse body of work exists for targeting this pathway as a
general antileukemic therapy, with studies limited to small in vitro studies using
established human cell lines, and single agent pharmacological inhibition of
MATIIA or SAHH.121 Thus, we rigorously investigated methionine deprivation
with and without inhibition of enzymatic mediators of the biosynthetic pathway in
vitro and in combination with SOC cytotoxic induction therapy in vivo, as a novel
epigenetic treatment paradigm for MLL-R leukemias.
Here, we show for the first time to our knowledge that perturbation of
Met/SAM metabolism is cytotoxic to MLL-FP expressing cells and induces
apoptosis and DNA damage. Furthermore, perturbation of this critical metabolic
pathway through methionine restriction or pharmacologic inhibition of SAH
metabolism resulted in alteration of intracellular metabolite pools and overall
methylation potential. Finally, we found that perturbation of Met/SAM metabolism
and subsequently methylation potential, alters histone methylation dynamics
globally and specifically at the DOT1L promoter, decreasing its expression and
function in MLL-FP expressing cell lines and patient cells. In vivo pharmacologic
perturbation of Met/SAM metabolism through SAHH inhibition, significantly
prolonged the survival of mice harboring aggressive MLL-R patient leukemia in
combination with a clinically similar regimen of cytotoxic induction therapy
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combining doxorubicin and cytarabine. Thus, targeting Met/SAM metabolism may
provide a novel therapeutic vulnerability against MLL fusion driven leukemia.

MATERIAL AND METHODS

Cell culture and Patient Samples. All established human leukemia cell lines
MV411, RS411, and K562 were obtained from American Type Culture Collection
(ATCC, Rockville, MD, USA) and cultured in standard RPMI medium
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at
37°C with 5% CO2. Patient derived xenografts (CCHC-7, CCHC-9, and CCHC23) were established and expanded at Cincinnati Children’s Hospital Medical
Center in NSGS mice from primary pediatric specimens aquired under an IRBapproved protocol following informed consent at time of relapse. Following
engraftment and expansion in NSGS mice, resulting in terminal leukemic disease
and euthanasia, we received the harvested BM aspirates from leukemic mice
frozen at -80°C in RPMI with 10% FBS and 10% DMSO until xenograft. CCHC-7
cells were also cultured in vitro in standard RPMI medium supplemented with
10% fetal bovine serum, 1% penicillin/streptomycin, and human cytokines (SCF,
FLT3L, TPO, IL-3, and IL-6) at 37°C with 5% CO2.

Annexin V/Propidum Iodide Staining for Apoptotic Cells. Cell death was
analyzed and quantified by FACS staining for Annexin V and propidium iodide
(PI). Briefly, cells were thoroughly washed twice with ice cold PBS following
exposure to experimental conditions and resuspended in 300ul of 1X Annexin
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binding buffer. Next cells were incubated with 1µL of anti-Annexin V antibody
conjugated to APC (catalog #640920, BioLegend San Diego, CA, USA) and 4µL
of 1 mg/ml PI solution (Sigma-Aldrich St. Louis, MO, USA) for 15 min at 4°C,
followed by analysis on a Becton Dickinson FACScan using FlowJo software.

Protein Isolation/Quantification and Western Blot Analysis. Protein was
isolated from cells in CHAPS lysis buffer, and quantified as previously
described.122 Western blot analysis was then conducted as previously described
using 30µg of protein for experiments involving total protein lysates and 15µg of
protein for experiments involving purified histones, using 1:5000 or 1:2000
dilutions respectively for primary antibodies and 1:20000 dilution of secondary
antibodies. Proteins of interest were then detected by addition of
chemiluminescence substrate.

SAM/SAH Reverse Competition ELISA. Intracellular metabolites were isolated
on ice by sonication of 10 x 10^6 cells per timepoint in 1ml of ice cold PBS using
a 30 kHz sonnicator with probe at 30% amplitude for three 20 second cycles with
one minute breaks between sonication. Cell debris was removed by high speed
centrifugation and the resultant supernatant was snap frozen in liquid nitrogen
and immediately stored at -80°C to prevent metabolite degradation.
Quantification of intracellular SAM and SAH concentration was then conducted
using the SAM/SAH ELISA Combo Kit from Cell Biolabs, INC. (catalog #STA671-C, San Diego, California, USA) following the manufacturers’ protocol.
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Histone Isolation. Histones were isolated from cellular nuclei by acid extraction
as follows. First cells were harvested and washed twice in ice cold PBS and then
resuspended in Triton Extraction Buffer(TEB: PBS containing 0.5% Triton X 100,
2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02% NaN3) at a cell density of 10 7
cells per ml per timepoint. Cells were lysed by ten minute incubation in TEB
buffer at 4°C with gentle stirring followed by centrifugation at 6500 x g for ten
minutes at 4°C to pellet the nuclei. The supernatant was discarded and the nuclei
resuspended and washed in half the original volume of TEB buffer, followed by
centrifugation as before. The supernatant was discarded and the nuclei pellet
was resuspended in 100µL of 0.2 N HCl and placed at 4°C overnight to acid
extract histones. The following day samples were centrifuged at 6500 x g for 10
min to pellet debris and the supernatant was collected and HCl neutralized by
addition of 10µL of 2M NaOH. Protein content was then determined using the
BCA assay.

Chromatin Immunopreciptation (ChIP). Chromatin fixation, isolation, digestion,
and immunoprecipitation was performed as previously described in detail. 123
ChIP antibodies detecting anti-H3K4me3, anti-H3K27me3, and anti-H3K79me2
were used for immunoprecipitation followed by ChIP quantitative RT-PCR as
described earlier using DOT1L promoter specific primers. Further, similar
quantitative RT-PCR was performed on immunoprecipitated chromatin using
primers designed against a non-specific region approximately 6 kb upstream of
the transcription start site (TSS) as a control to ensure that differential results are
truly DOT1L promoter specific and not technique driven. DOT1L promoter
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specific primers were designed just upstream of putative transcription factor
consensus sites as determined by MotifMap software, and a detailed promoter
map including primer binding sites can be found in Fig. 5A.

RT-PCR. RT-PCR was performed on immunoprecipitated genomic DNA (as
detailed above) or total isolated RNA reverse transcribed to cDNA as previously
described.122 Primers for qPCR were designed against the promoter sequence or
transcribed sequence using Primer Express 3.0 software (Applied Biosystems,
Foster City, CA) per the manufacturer’s instructions for SYBR green dye assays.
RT-PCR was performed using iTaq Universal Sybr Green Supermix (Bio-Rad)
and relative expression levels were analyzed using ΔΔCT method data was
normalized to 12.5% total chromatin inputs for RT-PCR following ChIP or β-actin
expression for experiments on reverse transcribed mRNA. PCR reactions were
analyzed on a BioRad CFX96, and a list of primer sequence and amplicon
lengths can be found in Supplementary Table 1.

Clinical Chemotherapeutics. Clinical formulations of both doxorubicin and
cytarabine were obtained from the James Graham Brown Cancer Center as selfsealing vials containing 20 mg/10 ml or 2g/20ml respectively dissolved in saline,
manufactured by APP a division of Fresenius Kabi USA LLC (Lake Zurich, IL).

In vivo xenograft studies. As previously described NRGS
(NOD/RAG1/2−/−IL2Rγ−/−Tg[CMV-IL3,CSF2,KITLG]1Eav/J, stock no: 024099)
mice producing 2-4 ng/ml of human IL-3, GM-CSF, and SCF108 were obtained
from Jackson laboratories, and bred and maintained under standard conditions in
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the University of Louisville Rodent Research Facility (RRF) on a 12-hour light/12hour dark cycle with food and water provided ad libitum. For all xenograft studies
NRGS mice received 1.25 x 10^5 human cells (CCHC-7 or CCHC-9) suspended
in 200µl PBS per mouse by bolus IV injection and n=5 for all study cohorts. Mice
were then injected with an isovolumetric bolus of the vehicle (PBS), or treated
with our previously described high intensity 5+3 induction regimen with or without
25 mg/kg DZA dissolved in 200µl.124

Statistical analysis. All statistics were performed using GraphPad Prism 8
software. Unless specified below significance was determined by one-way
ANOVA, followed by Tukey tests, using a cut off of P < 0.05. For all survival
curves the log rank (Mantel-Cox) test was used, with a cut off of P < 0.05.

RESULTS
Perturbation of Met/SAM metabolism impairs cellular viability and induces
apoptosis in MLL-FP expressing cell lines.
We first sought to examine changes in cellular viability induced by
alterations to Met/SAM metabolism on two MLL-AF4 expressing cell lines
representing distinct leukemic lineages, MV411 and RS411 (AML and T-ALL
respectively), as well as BCR-ABL driven K562 cells. We chose to target two
distinct nodes of Met/SAM metabolism namely the synthesis of SAM by
restriction of exogenous methionine, and downstream metabolism through
pharmacological inhibition of SAH hydrolase using the competitive inhibitor 3deazaadenosine (DZA), singly or in combination. Inhibition of downstream
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Met/SAM metabolism by DZA induced a dose and time dependent impairment of
cellular viability as quantified by Alamar Blue assay selectively in the MLL-AF4
expressing cell lines, but not MLL-FP independent K562 cells (Fig. 3.1A).
Similarly, decreasing concentrations of exogenous methionine also impair
cellular viability (Fig. 3.1B). Using the data obtained from both dose curves we
determined an appropriate concentration (15uM) of DZA, and timeframe to
investigate methionine deprivation without overt toxic effects, for all further
studies. Annexin V staining revealed that methionine deprivation and/or inhibition
of SAH metabolism potently induced apoptosis MV411 cells, with the
combination producing an additive increase in apoptosis. Interestingly, in the
timeframe investigated RS411 cells only underwent apoptosis in the presence of
DZA, but additive effects were still observed with simultaneous methionine
deprivation and DZA treatment. (Fig. 3.1C, middle) Conversely, K562 cells
lacking MLL-FP expression, were resistant to apoptosis induction through either
methionine deprivation or inhibition of downstream SAHH mediated metabolism
(Fig. 3.1C, right). Changes in protein expression corresponding the induction of
apoptosis, like cleavage of PARP-1 and Caspase-3 were observed selectively in
the MLL-AF4 expressing cell lines upon perturbation of Met/SAM metabolism,
and consistent with the aforementioned Annexin V staining data RS411 cells only
underwent apoptosis upon inhibition of downstream SAHH mediated metabolism,
while MV411 cells underwent apoptosis upon deprivation of exogenous
methionine or by SAHH inhibition (Fig. 3.1D).
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Figure 3.1 Perturbation of Met/SAM metabolism potently induces apoptosis
and reduces cell viability in established MLL-R leukemia cell lines . (A)
Dose and time dependent reduction in relative survival of MLL-AF4 expressing
MV411 (AML) and RS411 (ALL) cells treated with increasing concentrations DZA
as quantified by Alamar Blue vitality assay 48 hours post treatment. K562 cells
lacking MLL-fusion expression show no reduction in relative survival upon DZA
treatment. (C) From left to right; Methionine deprivation or exposure to 15µM
DZA potently induced apoptosis at 48 hours in MV411 cells singly, and the
combination showed an additive increase in apoptosis as determined by Annexin
V+ staining. RS411 cells only undergo apoptosis upon exposure to 15µM DZA
and this effect is amplified by methionine deprivation. K562 cells lacking MLL-R
show no induction of apoptosis 48 hour post DZA exposure or methionine
deprivation. (D) Changes in protein expression corresponding with apoptosis
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induction (PARP-1 and Caspase-3 cleavage) were observed under all
experimental conditions in MV411 cells (left), while RS411 cells only undergo
apoptosis upon DZA mediated SAHH inhibition (right).
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Perturbation of Met/SAM metabolism influences intracellular metabolite
pools, causing an increase in intracellular SAH and a decrease in
methylation potential in MLL-AF4 expressing cells.
After confirming that impairment of Met/SAM metabolism was selectively
toxic to MLL-FP expressing cells, negatively impacted cellular viability, and
induced apoptotic cell death we next sought to examine the impact on relevant
intracellular metabolites, namely SAM and SAH, using a commercially available
ELISA kit. These metabolites are of crucial importance as the ratio of intracellular
SAM and SAH determines the overall cellular methylation potential, and the
accumulation of SAH globally inhibits all methyltransferase reactions including
those required for epigenetic regulation of gene expression (Fig. 3.2A). 8 hour
exposure to 15uM DZA and/or methionine deprivation was sufficient to
significantly increase intracellular SAH in MV411 cells, with a likely synergistic
increase in SAH concentration upon simultaneous DZA treatment and
methionine deprivation. By 24 hours MV411 cells showed a significant increase
in intracellular SAH concentration under all conditions even methionine
deprivation alone, however the increase is least pronounced with simultaneous
methionine deprivation and DZA treatment, likely due to reduced metabolic flux.
(Fig. 3.2B, left) Similarly, RS411 cells also showed a significant increase in
intracellular SAH after 8hr or 24hr of exposure to DZA, but not simply by
methionine deprivation, and no apparent synergy was observed with combined
DZA treatment and methionine deprivation. (Fig. 3.2B, right) Interestingly, no
significant change in intracellular SAM was observed in either cell line under any
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of the experimental conditions including methionine deprivation suggesting these
cells exhibit some capacity to recycle Met/SAM from other intracellular metabolite
pools like homocysteine or 5-methylthioadenosine (Fig. 3.2C). Finally, we
determined the overall cellular methylation potential, expressed as the ratio of
intracellular SAM:SAH concentration normalized to untreated cells in methionine
rich media, and found that 8 or 24hrs of methionine deprivation or exposure to
DZA was sufficient to significantly lower overall cellular methylation potential in
MV411 cells (Fig. 3.2D, left). RS411 cells show no significant changes in
methylation potential upon short-term exposure to any experimental conditions,
but show significant changes at 24hrs. As expected treatment with DZA
significantly decreased cellular methylation potential with or without methionine,
but methionine deprivation alone actually significantly increased cellular
methylation potential in RS411 cells (Fig. 3.2D, right).
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Figure 3.2 Disruption of Met/SAM metabolism increases intracellular SAH
concentration and decreases overall methylation potential. (A) Simplified
schematic of Met/SAM metabolism showing important enzymatic mediators,
substrates and products. Deregulation of Met/SAM metabolism and subsequently
methylation potential was achieved by targeting two distinct nodes, either by
reducing synthesis of the methyl donor moiety SAM by methionine deprivation or
pharmacological inhibition of downstream SAH metabolism and methionine
recycling. (B) From left to right; Intracellular SAH concentration was increased in
MV411 cells under all experimental conditions and timepoints, while only DZA
mediated inhibition of SAH metabolism sufficiently increased intracellular SAH
concentration in RS411 cells. (C) No significant changes were detected in the
intracellular SAM concentration as compared to vehicle treated cells in
methionine rich media, in either MV411 or RS411 cells under any experimental
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conditions. (D) Overall cellular methylation potential (SAM:SAH) was significantly
reduced in MV411 cells 24 hours post exposure to experimental conditions.
RS411 cells only show significant reduction in methylation potential following 24
hour exposure to DZA, and conversely a significant increase in methylation
potential was observed following 24 hours of methionine deprivation.
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Methionine deprivation or inhibition of downstream SAH metabolism alters
global histone methylation dynamics in MLL-AF4 expressing leukemic cell
lines.
Next, we examined how perturbation of Met/SAM metabolism impacted
global histone methylation dynamics in both MV411 and RS411 cells, by Western
blot analysis on purified histone extracts. Initially, we chose to examine the most
common activating histone modification H3K4Me3, which is heavily enriched at
transcribed promoters, and the most common repressive modification
H3K27me3. Methionine deprivation and/or SAHH inhibition through DZA
treatment severely diminished global H3K4me3 levels in MV411 cells, while only
treatment with DZA resulted in a global increase of the repressive modification
H3K27me3 at all timepoints examined (Fig. 3.3A). RS411 cells show decreased
levels of global H3K4me3 only in conditions of methionine deprivation, and when
combined with DZA a more potent reduction is seen in the short term (Fig. 3.3B).
Similar to MV411 cells, RS411 cells show a time dependent increase in global
H3K27me3 only upon SAHH inhibition with or without methionine. MLL-R
leukemias have been shown to be uniquely dependent on the misdirected
enzymatic activity of the methyltransferase DOT1L to catalyze aberrant H3K79
methylation and activation of leukemogenic gene expression. We next examined
how perturbation of Met/SAM metabolism and methylation potential would impact
global levels of H3K79me2, a modification required for the survival of MV411 and
RS411 cells. Disruption of Met/SAM metabolism at either node dramatically
reduced global H3K79me2 at all examined timepoints in MV411 cells, indicating
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that they require sufficiently high levels of Met/SAM metabolic flux to maintain
global levels of H3K79me2 (Fig. 3.3C). Global H3K79me2 was also reduced in
RS411 cells at all timepoints examined (Fig. 3.3D)
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Figure 3.3 Perturbation of Met/SAM metabolism alters global histone
methylation dynamics and decreases DOT1L dependent global H3K79me2
in MLL-R leukemia cell lines. (A) MV411 cells display a dramatic reduction in
global levels of the activating H3K4me3 modification following methionine
deprivation or DZA treatment, and a global increase in the repressive H3K27me3
modification, only upon DZA mediated SAHH inhibition. (B) RS411 cells only
display reduced levels of H3K4me3 only under conditions of methionine
deprivation, but similar to MV411 cells show increased H3K27me3 after DZA
mediated inhibition of SAH metabolism (right). (C) MV411 cells have profoundly
reduced levels of MLL-R required H3K79me2 at all timepoints and experimental
conditions examined. (D) RS411 cells also show a loss in global H3K79me2 with
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differential reduction upon methionine deprivation and/or DZA treatment, but loss
of this modification occurs more slowly as compared to MV411 cells.
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Inhibition of SAH metabolism and/or methionine deprivation reduces
mRNA expression and protein levels of the H3K79 methyltransferase
DOT1L, and induces DNA damage.
Perturbation of Met/SAM metabolism significantly decreased global levels
of the required activating H3K79me2 modification in MV411 and RS411 cells.
Therefore, we next examined how alterations to Met/SAM metabolism impacted
the expression of the H3K79 methyltransferase DOT1L, at the mRNA and protein
level. MV411 cells show significantly reduced DOT1L mRNA expression
following 8hr treatment with DZA, with or without methionine deprivation, and by
24hrs all three conditions significantly diminish DOT1L mRNA expression (Fig.
3.4A, left). Consistent with the mRNA expression data, protein levels of DOT1L
are also diminished in MV411 cells, and interestingly DNA damage was observed
under conditions of DOT1L depletion (Fig. 3.4A, right). In alignment with
previous cytotoxicity data a decrease in DOT1L mRNA was only observed upon
DZA treatment of RS411 cells at 8 or 24hrs post exposure to experimental
conditions, however by 36hrs DOT1L mRNA levels are decreased in RS411 cells
upon methionine deprivation (Fig. 3.4B, left). Protein expression of DOT1L was
reduced upon exposure to DZA at 8 and 24hrs post treatment, and under all
experimental conditions by 48hrs, and again DNA damage was observed by
pH2.AX foci formation (Fig. 3.4B, right). Conversely, DOT1L mRNA expression
was significantly increased or remained unchanged in non-MLL rearranged K562
cells, and very modest changes were observed in overall DOT1L protein levels
(Fig. 3.4C). Finally, to further demonstrate correlation between Met/SAM
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metabolic status, DOT1L expression, and apoptosis induction we either DZA
treated RS411 cells for 24 hours followed by washout, or deprived RS411 cells of
methionine for 48hrs followed by re-plating in methionine rich media, and tracked
DOT1L and cleaved caspase-3 protein expression. As expected exposure to
DZA for 24hrs or methionine deprivation for 48hrs decreased DOT1L expression
and induced caspase-3 cleavage, followed by the subsequent increase in DOT1L
expression and decrease in caspase-3 cleavage during recovery in drug free
methionine rich media (Fig. 3.4D).
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Figure 3.4 Alteration of Met/SAM metabolism reduces mRNA and protein
expression of the required H3K79 methyltransferase DOT1L selectively in
MLL-R leukemia cells. (A) DZA treatment or methionine deprivation of MV411
cells significantly reduced DOT1L mRNA following 24 or 36 hour exposure to
experimental conditions (left) and these changes are reflected in DOT1L protein
levels (right). Reduction in DOT1L expression also correlated with the induction
of DNA damage as determined by pH2.AX formation, likely due to the critical role
DOT1L plays in regulation of the DNA damage repair response. (B) RS411 cells
display a significant reduction in DOT1L mRNA (left) and protein levels (right)
following DZA mediated SAHH inhibition, but not with methionine deprivation
alone at the timepoints studied. Eventually, methionine deprivation alone
significantly reduced DOT1L mRNA and protein expression in RS411 cells, and
again DNA damage induction was detected only under conditions of DOT1L
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reduction. (C) Non-MLL-R K562 cells lacking functional dependence on DOT1L
show no significant changes in DOT1L mRNA expression (left) 24 hours post
study initiation, however DOT1L mRNA was significantly reduced 36 hours after
DZA exposure, but was significantly increased following 36 hours of methionine
deprivation. Interestingly, modulation of DOT1L protein levels was observed even
in K562 cells (right), and pH2.AX foci formation was also detected only under
conditions of methionine deprivation in K562 cells. These results may suggest
that appropriate regulation of Met/SAM metabolism and one-carbon sensing may
directly play a more universal role in regulation of DOT1L expression and
function in multiple cell types, regardless of MLL-R mediated functional
dependence on DOT1L and H3K79 methylation.
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Decreased expression of DOT1L is correlated to changes in histone
methylation dynamics specifically at the DOT1L promoter.
Chromatin immunoprecipitation (ChIP) was conducted on MV411 and
RS411 cells under all experimental conditions, using antibodies against
H3K4me3 (data not shown) and H3K27me3 followed by RT-PCR using DOT1L
promoter specific primers. Promoter specific primer sets were designed against a
DOT1L promoter region just upstream of two major putative transcription factor
binding sites as predicted by MotifMap software. Control primers were also
designed at a distal arbitrary location as an internal control to ensure that
observed results were not due to technical bias (Fig. 3.5A). We found that
inhibition of SAH metabolism and/or deprivation of exogenous methionine
significantly elevated levels of the repressive H3K27me3 modification at the
DOT1L promoter in MV411 cells 24hrs and 48hrs post exposure to experimental
conditions, and there is likely a synergistic increase in H3K27me3 48hrs post
combined methionine deprivation and DZA treatment (Fig. 3.5B). As we
expected RS411 cells only showed increased levels of DOT1L promoter
H3K27me3, upon DZA mediated inhibition of SAH metabolism, again matching
with our previous cytotoxicity and expressional data in RS411 cells (Fig. 3.5C)
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Figure 3.5 Decreased expression of DOT1L is correlated to changes in
histone methylation dynamics specifically at the DOT1L promoter. (A)
DOT1L promoter map illustrating putative transcription factor binding sites as
determined by MotifMap software, as well as the specific binding sites of the
DOT1L promoter specific primers (P1) and the distal control primers. (B) MV411
cells show significantly elevated levels of H3K27me3 occupancy at the DOT1L
promoter following DZA treatment or methionine deprivation and by 48 hours an
additive increase was observed under simultaneous methionine deprivation and
DZA mediated SAHH inhibition. (C) RS411 cells exhibit significantly increased
DOT1L promoter H3K27me3 occupancy following 24 hours of simultaneous
methionine deprivation and DZA exposure, and by 48 hours DZA treatment but
not methionine deprivation alone is sufficient to significantly elevate DOT1L
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promoter H3K27me3 occupancy. (D) RS411 cells show a significant decrease in
mRNA levels of HOXA9 and MEIS1, two well established DOT1L targets known
to be required to maintain MLL-R mediated leukemogenesis, only upon DZA
mediated inhibition of SAH metabolism but not methionine deprivation alone in
agreement with our previous cytotoxicity and DOT1L expressional data in RS411
cells.
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Patient derived MLL-FP expressing leukemic blasts, similar to established
cell lines, are sensitive to alterations in Met/SAM metabolism, and show
corresponding changes in global and promoter specific histone
methylation dynamics.
We next examined if similar changes in histone methylation dynamics and
DOT1L expression and function could be observed in patient derived MLL-FP
expressing blasts (CCHC-7). CCHC-7 cells, bear an MLL-AF9 rearrangement
and grow under standard culture conditions with human hematopoietic cytokines.
We therefore plated these cells under all the previous experimental conditions
and similarly examined apoptotic effects, alterations to global histone methylation
dynamics, and changes in DOT1L expression. Like MV411 and RS411 cells,
CCHC-7 cells undergo apoptosis, as determined by immunoblotting for caspase3 and PARP-1 cleavage (Fig. 3.6A). However, the cytotoxic effects of
perturbation of Met/SAM metabolism in CCHC-7 cells more closely resemble
RS411 cells, in that only DZA induced inhibition of SAHH with or without
methionine resulted in apoptosis induction. Furthermore, we observed a
decrease in overall DOT1L protein expression and similar changes in global
histone methylation dynamics in the patient derived CCHC-7 cells, as compared
to the tested MLL-FP cell lines (Fig. 3.6B). Interrogation of the DOT1L promoter
by ChIP using a H3K27me3 specific antibody followed by RT-PCR using DOT1L
promoter specific primers, showed a significant increase in H3K27me3
occupancy at the DOT1L promoter in CCHC-7 cells (Fig. 3.6C). These results
are highly similar to our in vitro studies utilizing the established MLL-AF4
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expressing cell lines, we therefore felt confident in moving forward to in vivo
studies.
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Figure 3.6 Patient derived MLL-R leukemic blasts are sensitive to
perturbation of Met/SAM metabolism, and show changes in global and
DOT1L promoter specific histone methylation dynamics consistent with
tested MLL-R cell lines. Combining DZA with 5+3 induction therapy
significantly prolonged the life of mice harboring several different MLL-R
patient derived xenografts. (A) Patient derived CCHC-7 cells behave similarly
to the RS411 cell line and only undergo apoptosis following DZA mediated SAHH
inhibiton with or without methionine deprivation as determined by PARP-1 and
caspase-3 cleavage. Methionine deprivation for 48 hours was also sufficient to
induce apoptosis and PARP-1 and caspase-3 cleavage. (B) CCHC-7 cells show
a profound early loss in global H3K79me2 levels following 8 hours of exposure to
experimental conditions, and this reduction was more modest 24 hours post
exposure to either DZA or methionine deprivation alone. However, the
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combination of simultaneous DZA mediated SAHH inhibition and methionine
deprivation was still sufficient to decrease global H3K79me2 even after 24hrs
(top). DOT1L protein expression was also reduced in CCHC-7 cells by
methionine deprivation and/or DZA treatment (bottom). (C) CCHC-7 cell display
significantly elevated levels of DOT1L promoter H3K27me3 occupancy 24 or 48
hours after exposure to all experimental conditions and these changes likely
correlate with the observed reduction in DOT1L protein expression and function
(decreased H3K79me2). (D) NRGS mice (n=5 for all cohorts in all studies) were
xenografted with 1.25 x 10^5 CCHC-7, CCHC-23, or CCHC-9 patient leukemic
cells each bearing a unique MLL-R, and 7 days post xenotransplant mice began
bolus intravenous infusion of isovolumetric amounts of 5+3 induction therapy (3
mg/kg doxorubicin, Days 1-3 and 75 mg/kg cytarabine, Days 1-5), 5+3 induction
plus 25 mg/kg DZA (Days 1-5), or the vehicle PBS alone. DZA in combination
with 5+3 induction significantly prolonged the life of these mice as compared to
either 5+3 induction therapy or vehicle treatment alone in all xenograft studies
regardless of particular patient MLL-R, and excitingly two of the five mice bearing
CCHC-9 xenografts completely failed to develop leukemic disease and survived
till the endpoint of our study (far right).

94

Pharmacologic inhibition of SAH metabolism by DZA significantly prolongs
the survival of mice xenografted with patient MLL-FP expressing leukemia,
in combination with SOC induction therapy.
Patient derived CCHC-7 cells were found to be highly sensitive to
pharmacologic disruption of downstream SAH metabolism in vitro, and also
displayed similar changes in DOT1L expression, and both DOT1L promoter
specific and global histone methylation dynamics as compared to established
MLL-AF4 expressing cell lines. Thus, we finally examined the in vivo efficacy of
DZA mediated SAHH inhibition in a highly advanced and clinically relevant
xenograft model of patient MLL-R leukemia. Cohorts of transgenic NRGS mice
(n=5 per group) were xenografted with three induction refractory pediatric patient
AML samples, each bearing a different MLL rearrangement. Seven days post
xenograft the mice were given isovolumetric bolus intravenous injections of either
saline, induction chemotherapeutics, or induction chemotherapeutics combined
with 25 mg/kg DZA in a clinically similar and previously defined 5+3 regimen.124
Combined treatment using 5+3 induction and DZA significantly prolonged the
survival of NRGS mice xenografted with aggressive patient derived MLL-FP
expressing leukemia, albeit to varying degrees. A modest but significant survival
extension was seen in mice engrafted with either CCHC-7 or CCHC-23 cells, as
compared to 5+3 induction therapy alone (Fig. 3.6D left, center). Excitingly,
combinatorial therapy of mice harboring CCHC-9 leukemia significantly
prolonged their survival, and two of five mice in the (5+3) + DZA cohort survived
to the endpoint of the study without developing disease (Fig. 3.6D right).
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CHAPTER 4
OVERALL DISCUSSION AND SUMMARY

AML, and more broadly leukemia in general, is in actuality a heterogenous
group of related hematopoietic dysplasias characterized by a block in
hematopoietic differentiation, resulting in aberrant growth and proliferation.
Disease presentation of human leukemia is uniquely heterogenous among
cancers, and displays highly patient specific disparities in terms of morphology,
cytogenetics, and epigenetics. However, approved frontline clinical induction
therapy revolving around the cytotoxic combination of an anthracycline and
cytarabine remains the only FDA approved therapy for AML, and treats AML in a
“one size fits all” manner, regardless of patient specific disease etiology. Current
preclinical investigation of novel AML therapeutics very rarely involves
comparison to SOC chemotherapy. Furthermore, it has been well documented
that preclinical in vivo animal models of patient disease consistently better predict
the successful outcomes of novel experimental therapeutics in clinical trials.
Therefore, the overall goal of this dissertation was two-fold, first to develop a
more clinically relevant model of CDX or PDX AML that is capable of efficient
engraftment of patient AML, humanization, can model the influence of human
myeloid cytokine signaling, and most importantly tolerate an efficacious more
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clinically similar regimen of induction chemotherapy compared to the much more
prevalent SCID-dependent AML xenograft models.
Secondly, we sought to use our newly established advanced PDX model
of MLL-translocated pediatric leukemia to confirm preliminary in vitro findings that
perturbations of Met/SAM metabolism are cytotoxic to MLL-rearranged leukemia
cells and alter global and promoter specific histone methylation dynamics
decreasing the function and expression of the required H3K79 methyltransferase
DOT1L.
To address the first overall goal of developing a more advanced and
clinically relevant murine xenograft model, we compared the usefulness of the
relatively new and under-utilized SCID-independent immunodeficient NRG mice,
and the related human myeloid cytokine expressing NRGS strain without
preconditioning, in modeling of both malignant and normal human
hematopoiesis. Initially, we examined comparative engraftment efficiency of
human leukemic CDXs and PDXs in both NRG and NRGS mice. As expected,
we found that human primary and secondary PDX samples engraft with high
efficiency selectively in NRGS mice, but not NRG mice, likely due to their
transgenic expression of human myeloid cytokines whose signaling is required
for efficient engraftment. Remarkably, human CDXs showed irregular
engraftment and clinically disparate disease progression in NRGS mice resulting
in the formation of large IP and intra-lymphatic solid tumors, but showed
canonical diffuse hematopoietic restricted disease presentation and progression
in NRG mice. These effects are likely due to the constitutive whole body
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expression of human myeloid cytokines driving the rapid growth and proliferation
of established human leukemic CDXs in non-hematopoietic organs. Thus, our
findings highlight the importance of selecting the correct strain of mice as
contextually determined by the experimental design.
Importantly, we also examined therapeutic outcomes and tolerability of
SOC chemotherapeutic induction therapy, in a clinically similar 5+3 treatment
regimen, and showed therapeutic efficacy against human CDXs and PDXs.
Furthermore, these mice were tolerant of significantly higher doses of induction
chemotherapeutics, as compared to more commonly used SCID mice, and these
doses more closely recapitulate clinical patient therapy. Xenograft mouse models
have consistently been shown to better predict the success of experimental
chemotherapeutics in clinical trials, however most preclinical studies fail to also
model SOC therapy (usually only vehicle or less frequently single agent therapy
are used as study controls), both as a more relevant experimental control and
additionally in the study of combinatorial therapies. Our findings validate the
feasibility of modeling highly aggressive and clinically similar 5+3 induction
therapy in RAG1 deficient (SCID independent) NRG and NRGS mice, and similar
model systems may enhance investigation of highly efficacious novel singleagent or combinatorial chemotherapeutics.
In addition to modeling malignant human hematopoiesis, we also felt it
was important to examine the utility of these two under used mouse strains in
modeling normal hematopoiesis. Astonishingly, we found that even without
expensive and/or time-consuming ablative preconditioning NRGS mice were able
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to support the efficient durable engraftment and multilineage expansion of human
CD34+ UBC derived HSCs. These results are highly significant as they contradict
previous studies which demonstrate transgenic human hematopoietic cytokine
production is counterproductive and diminishes human HSC engraftment and
expansion. However, in contrast with the aforementioned studies for the sake of
ease, cost, and high-throughput efficiency we chose to forgo the intense ablative
preconditioning (pharmacological agents or irradiation) utilized in these studies,
opting instead to used unconditioned animals. Ablative conditioning may render
the murine BM microenvironment inhospitable to human HSC seeding or
promote hematopoietic differentiation and loss of self-renewal in human HSCs.
Thus, our findings indicate that not only is myeloablative conditioning
unnecessary in NRGS mice, and may in fact be detrimental to long-term durable
engraftment of human HSCs.
To address the second overall goal of this dissertation, we next sought to
utilize the aforementioned, and now well-characterized NRGS model system to
further investigate our in vitro findings that perturbations of Met/SAM metabolism
are cytotoxic, and deregulates the misdirected and required DOT1L / H3K79me
signaling axis required to maintain survival and leukemic potential in MLL-R
leukemia cells. We were able to show that perturbation of Met/SAM metabolism
by targeting two distinct nodes, namely through deprivation of exogenous
methionine or DZA mediated pharmacologic inhibition of downstream SAH
metabolism, induced apoptosis in established MLL-R cell lines and patient
derived MLL-R blasts, but not in MLL-R independent BCR-ABL expressing K562

99

cells. Furthermore, we determined that perturbation of this critical metabolic
pathway also resulted in changes in global and promoter specific histone
methylation dynamics including the global loss of the activating H3K4me3 and
H3K79me2, and an increase in the repressive H3K27me3 globally and
specifically at the DOT1L promoter, only in MLL-R leukemic cells. Interestingly,
we also observed that perturbation of Met/SAM metabolism even reduced both
mRNA and protein expression of the DOT1L methyltransferase, thus suggesting
that some degree of feed-back one-carbon metabolic regulation exists controlling
DOT1L expression and function in MLL-R leukemia cells. (Fig. 4.1)
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Figure 4.1 One proposed mechanism by which perturbation of Met/SAM
metabolism induces apoptosis in DOT1L dependent MLL-R leukemia cells.
Our findings suggest that perturbation of Met/SAM metabolism reduces
methylation potential and negatively impacts both expression and function of the
requisite H3K79 methyltransferase DOT1L in MLL-R cell lines and patient blasts.
Furthermore, under conditions of diminished methylation potential we observed a
significant decrease in global H3K79me2 and an increase in the repressive
H3K27me3 modification specifically at the DOT1L promoter, as well as a
reduction in DOT1L mRNA and protein. Given the unique dependence of MLL-R
leukemia on sufficiently high levels of DOT1L expression and function, our
findings suggest that perturbation of Met/SAM metabolism may be a novel
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therapeutic vulnerability specifically targeting the high levels of aberrant
activating histone methylation required to maintain MLL-R mediated
leukemogenic gene expression and phenotype.
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We next confirmed that similar changes in histone methylation dynamics
and cytotoxic effects occur in patient derived MLL-R leukemic blasts in vitro and
therefore felt confident in testing this novel therapeutic paradigm against MLL-R
PDXs, in our highly advanced in vivo human leukemia xenograft model.
Excitingly, the addition of 25 mg/kg DZA to our standard 5+3 induction therapy
regimen significantly prolonged the survival of NRGS mice bearing several
unique MLL-R patient samples as compared to vehicle or 5+3 induction alone
treated mice, and additionally no overt toxic effects were observed by weight
loss. These results are even more promising as all patient PDX cells were
acquired at the time of induction refractory relapse suggesting that perturbation
of Met/SAM metabolism may be a valuable therapeutic adjuvant, especially
during subsequent rounds of induction and/or consolidation therapy. Our studies
provides in vivo proof of concept that targeting Met/SAM metabolism may be a
unique vulnerability specifically against aggressive and poorly treated MLL-R
leukemia, by deregulating the expressional axis controlled by the MLL-R
epigenetic lesion. Finally, our findings also demonstrate the utility of our newly
established highly advanced PDX leukemia model, especially in the investigation
of novel combinatorial therapeutic treatment paradigms.
In total, work outline in this dissertation highlights the need for
implementation of more clinically relevant animal models of human leukemia, that
model not only physiologically relevant disease progression, but also response to
SOC cytotoxic induction therapy. Using our newly established mouse model of
human leukemia in NRG and NRGS mice, we were able to test the in vivo utility
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of targeting Met/SAM metabolism as a new treatment strategy specifically
against MLL-R leukemias, and were able to show significant life extension in all
mice treated in combination with DZA and 5+3 induction as compared to 5+3
induction alone. In conclusion, our findings demonstrate the utility of our newly
established murine PDX model, and furthermore provide support for the
continued investigation of perturbation of Met/SAM metabolism as a potential
new therapeutic approach against MLL-R leukemia in combination with SOC
cytotoxic chemotherapy.

STRENGTHS AND LIMITATIONS

STRENGTHS
The work presented in this dissertation, to our knowledge, is the first
comprehensive study of the utility of the under-utilized SCID-independent NRG
and NRGS mice in modeling malignant and normal human hematopoiesis.
Previous preclinical studies on experimental leukemia therapeutics have
depended heavily of chemotherapeutic intolerant SCID mouse models and
therefore fail to account for SOC treatment outcomes, as either a more relevant
control or in the investigation of adjuvant therapeutics. Our data conclusively
shows for the first time that both NRG and NRGS mice can tolerated relevant
doses of induction therapeutics in a clinically similar treatment regimen, and
therapy is efficacious in delaying disease progression and prolongs life of mice
harboring human CDXs or PDXs. Thus, our data challenges the hematological
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field to abandon the widely favored SCID dependent murine model systems, in
favor of RAG deficient strains tolerant of induction therapy, therefore not only
model the unique heterogeneity of patient leukemic disease, but more
importantly therapeutic response to SOC induction therapy. Truly efficacious
experimental anti-leukemia therapeutics must be judged in comparison to SOC
therapeutic outcomes, and additionally our new model system allows for
investigation of novel combinatorial therapies.
We next were the first to identify perturbation of Met/SAM metabolism as a
novel vulnerability in vitro and in vivo against the now well-defined MLL-R
epigenetic lesion, which maintains leukemogenic potential through aberrant
activating histone methylation and subsequent anomalous expression of
embryonic genes like the HOXA cluster or MEIS1. Our novel approach was to
investigate perturbation of Met/SAM metabolism, which controls both methylation
potential and methylation substrate availability, as a new therapeutic vulnerability
given MLL-R leukemia’s necessity to maintain high levels of aberrant histone
methylation to activate leukemogenic gene expression patterns crucial for
survival and disease progression. Perturbation of this metabolic pathway was
indeed toxic to MLL-R cells, induced apoptosis, and deregulated global and
DOT1L promoter specific histone methylation dynamics, providing support for our
initial hypothesis. We further demonstrated this point in vivo by showing
significant survival extension of mice when treated in combination with SOC
induction and the competitive SAHH inhibitor DZA as compared to induction
alone, in our newly described NRGS PDX model system.
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LIMITATIONS
While we believe our newly characterized, highly advanced, and more
clinically relevant human leukemia xenograft model is significantly superior to
more commonly used SCID dependent preclinical models, there are still
limitations to our NRG/NRGS model system. First and foremost, we demonstrate
that the utility of each of these relatively new mouse strains is contextually limited
by individual experimental design, more specifically NRG mice are well suited
only for CDX studies while NRGS mice develop clinically disparate CDX disease
progression, and should be used exclusively for highly efficient engraftment and
progression of PDXs. Secondly, while our collaborators at Cincinnati Children’s
Hospital have directly examined plasma levels of induction therapeutics in mice
and calibrated their doses based on mouse pharmacokinetics and clinical patient
plasma concentrations from literature, we have never directly examined plasma
drug concentrations in our mice, instead basing our doses on their published
studies. Regardless, our findings demonstrate the tolerability of these mice to
aggressive chemotherapy, to be double that of more commonly used SCID
dependent strains, and furthermore treatment is efficacious in prolonging survival
and human CDX and PDX disease latency.
Our work is the first to identify targeting of Met/SAM metabolism as a
potential therapeutic vulnerability against MLL-R leukemias, by deregulating the
required high levels of aberrant, activating DOT1L mediated H3K79 histone
methylation to maintain survival and leukemogenic potential. However, our
studies fail to elaborate on the essential nature of Met/SAM metabolism in a
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myriad of other critical cellular processes like purine/pyrimidine biosynthesis,
glutathione synthesis, 5-THF regeneration, etc. Perhaps our effects are mediated
more profoundly through decreased metabolic flux through these pathways
resulting in cytotoxicity and apoptosis induction. Furthermore, it is possible that
methionine deprivation induces other starvation related effects, like a global
decrease in all protein synthesis, and this may explain our observed decrease in
DOT1L expression. However, MLL-R independent K562 cells show no significant
change in global H3K79me2 levels and/or DOT1L mRNA and protein expression,
again suggesting that these effects only occur in the context of MLL-R leukemia.
Furthermore, differential effects were observed in sensitivity to targeting different
nodes of Met/SAM metabolism and may suggest that inhibition of this pathway is
only highly cytotoxic in MLL-R leukemias of myeloid origin or with other favorable
cell type intrinsic characteristics.
Finally, we were able to use our newly established NRGS PDX model
system to demonstrate significant life extension in mice treated with a
combination of SOC induction therapy and the SAHH inhibitor DZA, but never
investigated single-agent DZA therapeutic outcomes, and our studies were
limited by exclusively focusing on survival. Thus, we have no data from patient
leukemic cells isolated from PDX bearing NRGS mice, showing concurrent
changes in histone methylation dynamics as compared to our in vitro studies.
Furthermore, perturbation of Met/SAM metabolism may likely show additive
and/or synergistic effects with DNA-damaging induction chemotherapeutics, a
possibility that remained uninvestigated in our studies. These limitations were
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taken into consideration, however considering this was the first preliminary
investigation into targeting of Met/SAM metabolism in MLL-R leukemia, we
simply wanted to investigate potential differential adjuvant therapeutic outcomes
to determine whether this treatment paradigm was meritorious of future
investigation. Furthermore, no clinically useable inhibitors of any Met/SAM
metabolic enzymes exist, and most preclinical investigation, including this
dissertation, relies on relatively non-specific substrate competitive inhibitors
(cycloleucine, DZA, DZNep, adenosine dialdehyde, etc.). This changed in 2017,
when a group from Pfizer discovered and characterized PF-9366 the first novel
allosteric inhibitor of MATIIA, the enzyme responsible for the synthesis of SAM
from methionine, capable of inhibition at physiologically reachable
concentrations. Our findings now support the continued investigation of potent
targeted inhibitors of Met/SAM metabolism, as a unique vulnerability specific to
MLL-R leukemias.

FUTURE DIRECTIONS
While we have worked to extensively characterize and validate the utility
of NRG and NRGS mice in modeling both normal and malignant human
hematopoiesis, and further utilized our newly established model system to
confirm our in vitro findings that perturbation of Met/SAM metabolism may be a
unique therapeutic vulnerability in MLL-R leukemia. However, several important
underlying mechanisms and questions remain unanswered in our studies, and
thus the future directions are outlined below:
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1. Optimization of both induction therapeutic dosing and timing in NRG and
NRGS mice.

We have shown that NRG and NRGS mice are tolerant of aggressive 5+3
induction with 3 mg/kg doxorubicin and 75 mg/kg cytarabine, but
widespread toxicity and decreased survival was observed when the
concentration of doxorubicin was doubled to 6 mg/kg, irrespective of
cytarabine dosage. Interestingly, the few mice that did survive our dose
escalation study actually survived until the 100 day study endpoint with no
symptomatic leukemic disease progression. These findings are highly
exciting as they suggest that with careful optimization of the dose limiting
anthracycline, we may be able to model the most predominant clinical
outcome of leukemia, initial remission. Further, aging of the PDX
harboring mice that receive remission inducing induction therapy, may
actually allow for the development of refractory patient disease, even
further increasing the preclinical modeling utility of the NRG/NRGS model
system. In the future we also plan to examine how modulation of induction
timing affects therapeutic outcomes, and to model other approved
induction regimens like 7+3 therapy.
2. Investigate the in vivo therapeutic potential of dietary methionine
restriction in mice harboring human leukemia xenografts.

Data outlined in Chapter 3 indicate that perturbation of Met/SAM
metabolism by pharmacologic inhibition of SAHH using 25 mg/kg DZA
significantly prolonged the survival of NRGS mice harboring aggressive
patient MLL-R leukemia, in combination with 5+3 induction. However, the
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therapeutic potential of dietary methionine restriction and 5+3 induction
remains unstudied. In order to examine these potentially beneficial effects,
we have established and treated two cohorts of NRGS mice harboring the
same MLL-R PDX, and each cohort is fed either isocaloric chow
containing 0.86% or 0.11% methionine respectively. Previously published
studies have shown that modulation of dietary methionine is sufficient to
alter histone methylation dynamics in mice and humans.125,126 Additionally,
we may also observe toxicity ameliorative or chemotherapy enhancing
effects, as several other studies have shown beneficial effects of
methionine restriction on chemotherapeutic drug efficacy and tumor
regression.127-129
3. Examine therapeutic efficacy of combined DZA treatment and methionine
restriction with 5+3 induction against patient MLL-R xenografts.

Our final line of future investigation aims to combine the observed
beneficial effects of DZA treatment along with 5+3 induction, with the
potential benefits of dietary methionine restriction. These studies may
demonstrate even further enhanced improvement in treatment outcomes
and amelioration of chemotherapeutic toxicity, especially if beneficial
effects are seen in the studies described above combining dietary
methionine restriction and 5+3 induction therapy. Further investigation
may reveal targeting of Met/SAM metabolism as a bona fide therapeutic
vulnerability inhibiting the aberrant activating histone methylation driven by
the MLL-R epigenetic lesion.
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ABBREVIATIONS

AML

Acute myeloid leukemia

BM

Bone marrow

SOC

Standard of care

FAB

French-American-British

APL

Acute promyelocytic leukemia

WHO

World Health Organization

CR

Complete Remission

IV

Intravenous

Ara-c

Cytarabine

MRD

Minimal residual disease

CN-AML

Cytogenetically normal AML

NPM1

Nucleophosmin 1

FLT3

Fms-like tyrosine kinase

DNMT3A

DNA methyltransferase 3A

FLT3-ITD

FLT3 Internal Tandem Duplication

OS

Overall survival

DFS

Disease free survival

HSC

Hematopoietic stem cell

HMT

Histone Methyltransferase

HDAC

Histone Deacetylase

MLL

Mixed-lineage leukemia

ALL

Acute lymphocytic leukemia
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SEC

Super elongation complex

DOT1L

Disruptor of telomeric silencing 1-like

MLL-FP

MLL fusion protein

SAM

S-adenosylmethionine

Met

Methionine

MATIIA

Methionine adenosyltransferase IIA

SAH

S-adenosylhomocysteine

SAHH

S-adenosylhomocysteine hydrolase

MTR

Methionine synthase

LSC

Leukemic stem cell

SCID

Severe combined immunodeficiency

Prkdc

DNA-activated catalytic polypeptide

NOD

Non-obese diabetic

RAG

Recombination activated gene

NK

Natural killer

SF

Steel factor

SCF

Stem cell factor

UBC

Umbilical cord blood

RRF

Rodent research facility

IP

Intraperitoneal

HSCT

Hematopoietic stem cell transplant

ChIP

Chromatin immunoprecipitation

PI

Propidium iodide

TSS

Transcription start site
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